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Abstract 
Alzheimer's disease is a neurodegenerative disease characterized by the 
deposition of amyloid plaques and neurofibrillary tangles in the brain. The deposition 
of amyloid plaques is formed by aberrant processing of amyloid precursor protein 
(APP), resulting in the generation of neurotoxic 40-42 peptides Ap. Therefore, the 
understanding of the formation and clearance of Ap is crucial for drug development. 
In this study, a brain specific serine protease neurosin was characterized. The 
expression level of neurosin in cerebrospinal fluid is much higher in AD patients than 
normal. Neurosin is also expressed at high levels in inflammatory cells in multiple 
sclerosis patients. Neurosin degrades myelin basic protein in multiple sclerosis and 
a-synuclein in Parkinson disease, Neurosin is proposed to play a role in APP 
metabolism and processing. In this study, neurosin was cloned and characterized in 
order to evaluate its potential as drug target for Alzheimer's disease. 
In first part of the thesis, human neurosin was cloned and expressed in E.coli. 
Functional recombinant neurosin was successfully produced in E.coli expression 
system by co-expression with various molecular chaperones. Enzymatic analysis of 
recombinant neurosin indicated that it has substrate specificity for C-terminal 
arginine residue. In the second part of the thesis, the role of overexpression of 
neurosin was studied in rat neuroblastoma cell line B103. B103 is an APP-deficient 
clone that has been used for the study of APP metabolism. To facilitate the 
characterization of APP processing, human APP695 and its mutant forms were cloned 
by RT-PCR from a human brain cDNA library and subcloned into various 
mammalian expression vectors. These vectors were used to transfect B103 cells and 
the expression of APP was examined by Western blots on the cell lysates. APP was 
expressed as a 〜100 kDa protein detected by a monoclonal antibody 6E10 which 
recognizes the Ap epitope. The localization of APP and its C-teraiinal fragments 
fused to green fluorescent protein was also examined by laser confocal microscopy. 
While APP was predominantly expressed in the perinuclear and nerve terminals, the 
C-terminal APP-C59 was particularly expressed in the nucleus. Co-expression of 
neurosin with APP in B103 cells indicated that neurosin decreased the cellular level 
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Chapter 1 General introduction 
1.1 Introduction 
Alzheimer's disease (AD), named after Dr Alois Alzheimer, is the most 
common neurodegenerative disease among the ageing population. AD is the most 
common cause of age-related dementia in the elderly over 60 that affect their normal 
lives. In severe case, people suffered from AD require hospitalization and nursing 
care. It is becoming a major heath-care issue in the developed countries as it is 
expected a rise in the proportion of population over 60 in the next twenty years. With 
the advances in study of cell and molecular biology of AD over the past three 
decades, the mechanism of the pathogenesis of this disease is beginning to unveil. As 
was originally described by Dr. Alzheimer, two distinct hallmarks of this disease 
were noted from the study of postmortem brain sections; the depositions of amyloid 
plaques and the appearance of tau-rich neurofibrillary tangles (NFT) in neurons. The 
amyloid plaques are formed by the insoluble starch-like protein aggregates found in 
different brain regions of AD patients. The main component of amyloid plaques is 
the amyloid p protein (Ap) resulting from the abnormal processing of a 
membrane-bound protein known as amyloid precursor protein (APP). On the other 
hand, the main component of NFT is paired helical filaments (PHF), resulting from 
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the unusual assembly of hyper-phosphorylated tau proteins. According to these two 
pathological features, two seemingly independent hypotheses were proposed. The 
first hypothesis is known as the amyloid cascade hypothesis, accounting for the 
biochemistry of the formation of amyloid plaques. The other is known as the 
neuronal cytoskeletal degenerative hypothesis (tauopathy hypothesis), aiming to 
explain the biochemical consequence of neuronal cell death due to the formation of 
NFT. Despite extensive research, it is still poorly understood how the two hypotheses 
reconcile. It has been well documented that the formation of senile plaques always 
precedes the NTF formation as in the case of early-onset AD in patients suffered 
from Down's syndrome. There is increasing evidence that these two hypotheses are 
not mutually exclusive to each other and may be linked together by a common 
biochemical pathway that causes the disease (Kim et al. 2003). Recent evidence 
points to the key processing enzyme responsible for amyloid precursor protein (APP) 
processing, the presensilin, that provides a clue for the linkage between the two 
hypotheses which wil l be discussed in more details in the later section. 
1.2 Pathogenesis of Alzheimer's disease 
1.2.1 Amyloid cascade hypothesis 
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The amyloid cascade hypothesis suggests that the amyloid accumulation and the 
signaling events associated with the pathology of amyloid formation is the cause of 
AD. This hypothesis is mainly based on the studying the mutations found in familial 
AD patients. Missense mutations genes that include the amyloid precursor protein 
(APP), presenilin 1 (PSl) and presenilin 2 (PS2) were found to be associated with 
early onset familial AD. Another piece of evidence comes from Down syndrome (DS) 
patients, who develop AD at the age of 30-40 (Lemere et al. 1996), suggesting a 
genetic linkage on gene of chromosome 21. Ap, the 40-42 residues peptides 
constituent of amyloid, is the secreted peptides from the processing of APP by at 
least three different processing enzymes. Transgenic mice carried human APP 
mutations was found to develop AD with plaques formed in brain (Games et al. 1995; 
Hsiao et al. 1996), supporting the hypothesis that AD is caused by an abnormal 
processing of APP. 
Ap is produced from sequential cleavage of APP. There are two major forms of 
Ap, AP40 and Ap42. Ap42 is the minor product but is found to play a critical role in 
AD pathogenesis. For instance, APP/PS mutations cause Ap42 accumulation in DS 
children. DS patients develop diffuse plaques at late first decade and early second 
decade, but not showing full-blown AD histopathology until the third or fourth 
decade (Gouras et al. 2000). Ap42 is more prone to aggregate to amyloid protein 
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(Jarrett et al. 1993). A(340 is less likely to be fibrillogenesis and may co-deposit in 
later stage. However, it is questionable whether Ap40 alone is responsible for plaque 
formation because most plaques are made up of Ap42 in PS mutations FAD patients. 
The toxicity of Ap42 has been studied thoroughly in vitro by many groups of 
scientists on different aspects, for instances, in inflammatory response, oxidative 
injury and altered calcium homeostasis. Accumulation of Ap42 and plaques activates 
microglia (macrophage-like) in plaques and produce pro-inflammatory cytokines 
(McGeer et al. 1995). The plaques also trigger classical pathway of complements, 
attacking by membrane associated complex leading to cell death (Itagaki et al. 1994). 
In addition, the inflammatory response generates excessive reactive oxygen species 
(ROS), damaging proteins and lipids. It seems Ap42 alone can trigger the generation 
of ROS. The accumulation of Ap42 alters ionic homeostasis, particularly calcium 
ions, by inserting cation channels. The excessive calcium entry eventually causes cell 
death (Mattson et al. 1992). The combined effects of Ap42 activate certain kinases, 
such as glycogen synthase kinase 3p (GSK3p) or cyclin-dependent kinase 5 (cdk5). 
These kinases wi l l hyperphosphorylate tau and cause tangles formation. 
1.2.2 Tauopathy 
The second hallmark of AD is neurofibrillary tangles (NFT). NPT is a large 
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non-membrane bound bundles of abnormal fibres that occupy most of the perinuclear 
cytoplasm. NFT composes of paired filament (〜lOnm) wound in helices (paired 
helical filament, PHF), which is made up of aberrantly phosphorylated tau proteins. 
PHF is not soluble in strong denaturant (such as SDS) (Lee et al. 1991) and 
protease-resistant (Wischik et al. 1988). 
The normal function of tau is to stabilize microtubules (Weingarten et al. 1975). 
Tau protein promotes tubulin dimer (a and (3) polymerization and maintains 
microtubules stability (Khatoon et al. 1995). The tau protein is hyperphosphorylated 
by GSKSP and cdk5. The negative charges of phosphate groups neutralize the basic 
groups of tau (Tau is an Arg/Lys rich protein), thus faciliting the aggregation of tau 
(Alonso et al. 2001). How plaque formation leads to tangles formation remains 
obscure, although plaque formation always precedes tangles formation in many 
clinical observations. 
1.3 The amyloid precursor proteins 
1.3.1 Structure of amyloid precursor proteins and related peptides 
Amyloid precursor proteins are a family of transmembrane proteins comprising 
amyloid precursor protein (APP), amyloid precursor protein-like proteins (APLPl, 
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APLP2) in human. Conserved orthologs are also found in other organisms; i.e. APPL 
in D.melanogaster and APL-1 in C.elegans (Coulson et al. 2000). They share similar 
structural features with a large extracellular domain, a short transmembrane domain 
and a C-terminal cytoplasmic tail. Several conserved sub-domains or motifs were 
identified; the heparin-binding domain, collagen-binding domain, zinc-binding 
domain and clathrin (YENPTY) attachment domain conserved in entire family. 
Kunitz protease inhibitor domain was found in APP and APLP2 only. APP and 
APLP2 expressed ubiquitously while APLPl limited its expression in the brain. The 
generation of Ap is conserved among different organisms, indicating a pivotal role of 
APP in cellular functions. However, despite extensive research over the last three 
decades, there is little consensus about the exact physiological functions of APP and 
APLPs and their processed products. Mice with single knockout of APP, APLPl or 
APLP2 are fertile and viable; however, they have various degrees of defects such as 
commissure defects, hypersensitive to epileptic seizures (Steinbach et al. 1998) and 
reduced body weight (Heber et al. 2000) 
1.3.2 Amyloid precursor protein mutations 
It has been known that typical AD can be found in clusters in families inherited 
in autosomal dominant fashion. The cases of familial AD (FAD) account for about 
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5-10% of AD. Indeed, the phenotype of FAD is similar to sporadic AD except for 
earlier onset (50-60) and dominant inheritance. The common features of FAD and 
sporadic AD, such as plaque and tangle formation, suggesting they have common 
pathogenesis mechanisms. 
Mutations found in APP are strongly associated with early onset FAD. Many of 
these mutations are clustered around the residues flanked between the A(3 processing 
sites cleaved by different proteases (a, (3 and y cleavages). Fig. 1-1 shows a summary 
of currently known mutations on APP that causes FAD found in genetic studies. 
Mutations around P-cleavage site include KM670/671NL, A673T, H677R and 
D678R. All these mutations increase the susceptibility APP to P-secretase, leading to 
Ap overproduction. Mutations around a-cleavage site include A692Q E693Q/K/G 
and D694N. Such mutations cause specific phenotypes such as cerebral haemorrhage, 
stroke and congophilic amyloid angiopathy (CAA) in addition to typical AD 
phenotypes. The mutations are likely to decrease the accessibility of a-secretase, 
leading to Ap overproduction. Mutations around y-cleavage site include T714I， 
V715M/A, I716V/T, V717F/I/G/L and L723P. These mutations increase A|342/Ap40 
ratio. The increase in Ap42 wi l l lead to plaque formation and AD pathogenesis. 
Mutations of presenilins also lead to FAD by altering the activity of y-secretase since 
presenilin is the catalytic core unit of y-secretase complex. Hence, the location of 
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mutations provided critical insight to mechanism of APP processing. 
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Fig 1-1 The structure of APP and mutations found in familial AD. Ap is formed by 
proteolyic cleavages at P and y sites, is shown as pink box. The sequence of Ap is 
highlighted in red box. FAD mutations are shown below the primary sequence of 
wild-type APP at this region. For example, the Swedish mutation APPsw has APP 
gene APP670/671KM mutated to APP670/671NL 
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1.3.3 Amyloid precursor protein processing 
Ap is produced by sequential processing of APP. In fact, APP is not the only 
protein processed in this way. Various type I integral membrane proteins such as 
Notch, CD44, N-cadherin; all undergo similar processing (Okamoto et al. 2001; 
Marambaud et al. 2003; Mumm et al. 2000). Researchers are particularly interested 
in comparing the processing events between APP and Notch. Most of our 
understandings in regulated membrane proteolysis come from exploring the 
processing of these two proteins. 
Notch is a 300 kDa protein (about 2,200 amino acid residues) that is processed 
by furin-like convertase (Logeat et al. 1998) (SI site). However, no similar 
processing site was found in APP. SI processing produces large extracellular domain 
and short membrane bound stalk domain. The heterodimers linked by noncovalent 
Ca^^-dependent structure (Rand et al. 2000). The larger domain has 36 EGF-like 
repeat domains which are responsible for Notch ligand binding and smaller domain 
has three Ca^ "" Notch/lin-12 repeats (LNR). On the other hand, APP possesses Cu^^ 
binding domain and heparin/collagen binding domains (which facilitates cell 
adhesion). Nevertheless, both APP and Notch are cleaved by a-secretase (S2 site), 
a-secretase cleaves APP constitutively but not Notch. Notch is processed by 
a-secretase when ligands bind and change the structure of Notch receptor (Rebay et 
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al. 1991). On the contrary, APP can be cleaved by P-secretase instead of a-secretase, 
which was not found in Notch processing. This cleavage event removes the large 
extracellular domain, hence called ectodomain shedding. Ectodomain shedding is a 
prerequisite for y-secretase processing. In fact, it seems all type I integral membrane 
proteins processed by y-secretase when the length of soluble domain below 300 
residues (by ectodomain shedding), y-secretase processing is more complicated 
because it can process multiple sites and the substrate specificity is loose, i f any. 
y-secretase can cleave at middle of transmembrane domain and near C-terminal of 
transmembrane domain. However, the cleavage events can occur simultaneously or 
independently. In the case of APP and Notch, y-secretase can process both sites. For 
clarity, the processing at the middle of transmembrane domain called y-cleavage site 
or S4 site while the processing at the edge of transmembrane domain called 
8-cleavage site or S3 site. In APP processing, Ap/p3 is formed by y-cleavage, along 
with APP intracellular domain (AICD) formation. In Notch processing, Notch 
intracellular domain (NICD) is formed by S3 processing, along with Np formation 
(analogy to Ap) (DeStrooper et al. 1999; Mumm et al. 2000). Notably, both AICD 
and NICD can mediate transcription through entirely different mechanisms. In 
addition, the size of AICD (-50 aa) is much smaller than NICD (-1000 aa). The 
major physiological function of Notch is mediated Notch signalling through NICD. 
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NICD has six tandem ankyrin repeats (Wharton et al. 1985) and nuclear localization 
signal. NICD displaces SMRT corepressor that converts CSL, a DNA-binding 
protein, from repression to activation (Zhou et al. 2000; Tani et al. 2001). The lateral 
inhibition mediated by Notch signalling is essential for neurogenesis, regulating the 
number of cells at each stage during neurogenesis. The deficient in Notch disrupts 
neural tube formation and causes early lethality (E9.5). On the other hand, AICD has 
phosphotyrosine binding (PTB) domain that bind adaptor proteins (XI1, Fe65, JIP), 
mediating several functions including gene transcription (Cao and Sudhof, 2001). 
1.3.4 Physiological roles of APP 
APP has three predominant isoforms, known as APP695, APP751 and APP770. 
The difference between APP751 and APP695 is that APP751 contains an extra exon 
(exon?) that encodes Kunitz protease inhibitor (KPI) domain. KPI domain may have 
a function to inhibit serine protease. APP770 has an additional exon (exon 8) 
compared to APP751. Exon 8 encodes an ox-2 like domain but the function of which 
remains unclear (Coulson et al. 2000). APP is expressed ubiquitously in many 
peripheral tissues. However, the APP695 is mainly expressed in the brain while 
APP751/770 mainly expressed in other tissues. 
APP has been suggested to function as a cell surface receptor because of similar 
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biochemical feature homologous to the processing of Notch signalling pathway. The 
soluble ectodomain of APP has been demonstrated to have growth factor-like activity, 
stimulating neurite outgrowth and enhancing cell adhesion in neuronal cultures. Two 
heparin binding domains corresponding to APP96-110 and APP316-447 were found 
that are able to bind extracellular matrix, heparin sulphate proteoglycans (HSPG) 
(Small et al. 1994). The penta-peptide corresponding to APP328-332 (RERMS) was 
also found to promote neurite outgrowth (Ninomiya et al. 1993). 
Another physiological function of APP is to regulate Cu^^ homeostasis. The 
cysteine-rich domain of APP 135-156 has copper binding ability and has capacity to 
2+ + 
facilitate the reduction of Cu to Cu，together with the formation of disulphide bond 
at residue 144 and 158 (Multhaup et al. 1998). Comparing the copper level in the 
cerebral cortex and liver of APPwt and APP -/- mice, it was found that copper level 
was significantly elevated (40% increase). In addition, the copper binding domain of 
APL-1 (APP homolog) in C.elegans was found to protect against copper 
neurotoxicity in vivo. However, APP-Cu(I) complex was unstable and more 
susceptible to random fragmentation at low concentration of H2O2 (oxidative stress). 
The formation of copper-hydroxyl radical intermediate [APP-Cu(II).(OH)] facilitates 
protein degradation. This may cause cytotoxicity because of free radical homeostasis 
disturbance. The discrepency between in vivo and in vitro experiments reveals the 
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complexity of biometal homeostasis. 
There is emerging evidence that the C-terminal tails of APP mediates its 
trafficking and proteolysis through interaction of various cytoplasmic proteins at 
different consensus motifs. The protein PATl (Protein interacting with APP-tail 1) 
binds to this motif, mediating intracellular transport of APP through secretory 
pathway (Zheng et al. 1998). The second motif, YENPTY that is conserved in the 
entire APP family, is essential for clathrin-coated vesicles internalization. The 
adaptor proteins such as Fe65, X I1 and JIP family members bind to this motif by 
interactions with the phosphotyrosine binding (PTE) domain (King and Scott Turner 
2004). 
Three members of Fe65 family have been identified, namely Fe65, Fe65Ll and 
Fe65L2. Fe65 is mainly expressed in brain and developmentally regulated. Fe65 
binds to APP cytoplasmic tails through the PTE domain, mediating cytoskeletal 
dynamics and cellular motility (Kesavapany et al. 2002). The main function of Fe65 
is likely to increase the processing of APP (Chang et al. 2003). 
Members of JIP (c-jun N-terminal kinase interacting proteins) included JIP-la, 
JIP-lb, JIP-2 (Matsuda et al. 2001). JIP-la and JIP-2 bind weakly to APP, their effect 
on APP processing is negligible. JIP-lb increases APP threonine-668 
phosphorylation that appears to affect kinesin light chain binding (Inomata et al. 
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2003). 
Other adaptor proteins such as APP-binding protein 1 (APP-BPl), disabled-1 
(Dab-1) (Homayouni et al. 1999), UV-damaged DNA binding protein (UVDDB) 
(Watanabe et al. 1999), autosomal recessive hypercholesterolemia (ARH) protein 
(Noviello et al. 2003) also binds to the YENPTY motif of APP. A complete 
understanding of the significance of the interactions of various adaptor proteins to 
APP may help to elucidate the mechanism of APP pathogenesis. Figure 1-2 
summarizes the interacting domains of APP to various adapter proteins. 
Recent evidence suggests that APP may play a role in axonal transport, serving 
as a receptor for axonal transport protein kinesin (Kamal et al. 2000; Muller and Kins 
2002). APP participates as a kinesin receptor bridging the kinesin light chain to 
APP-containing vesicles (Kamal et al. 2000). This is further confirmed by the 
observation that overexpression of mutated form of APP in APPL-deficient 
Drosophila caused organelle accumulations (Gunawardena and Goldstein 2001). This 
finding raises the possibility that APP plays a role in axonal transport and disruption 
of APP-mediated kinesin-dependent axonal transport causes neuronal death and AD. 
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Fig 1-2 Protein interactions of cytoplasmic tail of APP 
The X I1 family, Fe65 family, JIP family, Dabl and ARH all contain PTB domains 
interacting with YENPTY motif of APP. Additional sequence may be required for 
stabilization and interactions. She and Abl only interact with APP when tyrosine 
(YENP) is phosphorylated. PATl interact with YTSI domain. 
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1.3.5 The pathophysiological role of Ap 
Ap was originally found to be the main component of amyloid plaques and was 
later found to mediate neurotoxicity to the cells in cultures (Alvarez et al. 1999). The 
combination of extracellular plaques and intracellular tangles mediates toxicity to the 
cells. Surprisingly, AP was found to be normal physiological products (Estus et al. 
1992), depositing in many brain regions without degeneration (Joachim et al. 1989). 
In recent years, the attention shifts to soluble, oligomeric and intracellular Ap 1-42 
(Wilson et al.l999) as Ap 1-42 is more readily to aggregate in plaques and fibrils 
(Neve et al. 2000). 
Ap alters Ca^^-medaited neurotoxicity (Mattson et al. 1992; Weiss et al. 1994; 
Green and Peers, 2001). Ap also mediates toxicity by generation of reactive oxygen 
species (ROS) (Varadarajan et al. 2000). Such oxidative stress wil l lead to 
modification of proteins (eg, advanced glycation endproducts) and release of lipid, 
cholesterol and monosialoganglioside (Michikawa et al. 2001). The integrity of lipid 
bilayer disrupted. In turn, oxidatively damaged lipid bilayer promotes p-sheet 
formation of Ap to mediate toxicity again. This positive feedback loop of cellular 
dysfunction finally killed the cells. Accumulation of plaques causes microglia and 
astrocytes activation (Chong et al. 2001) and secretes wide range of interleukins and 
cytokines to mediate inflammatory response. Kim et al. (2002) reported the release 
17 
of cytochrome c from mitochondria induced by Ap, causing programmed cell death. 
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Fig 1-3 AP toxicity 
Ap exerts toxicity through (1) alteration of calcium homeostasis, (2) free radical 
generation, (3) inflammatory response and (4) activation of signalling pathway. The 
combination of these reactions causes cell death. 
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1.3.6 The pathophysiological role ofAPP-CTF 
APP-CTF refers to 16-22 kDa C-terminal processed fragments of APP that are 
immunostained in tangles (Yamaguchi et al. 1990) and plaques (Yamaguchi et al. 
1990). One of the major products, C99, can be produced by secretory cleavage of 
APP found in cerebral white matter (Tokuda et al. 1995) and optic nerves 
(Amaratunga and Fire, 1995). CTF but not Ap also mediated toxicity by inducing 
strong non-selective inward currents in Xenopus oocytes (Fraser et al. 1996, 1997). 
Another prominent CTF-induced toxicity is the disruption of ion homeostasis. The 
effect of ion imbalance is similar to Ap-induced toxicity. CTF decreases Ca^^ uptake 
in rat brain microsomes, increasing intracellular Ca^^ concentration that makes the 
cells more vulnerable to glutamate toxicity. When CTF injected to the mice, it caused 
significant learning and memory impairment (Song et al. 1998). 
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Fig 1-4 Toxicity of APP C-terminal fragments 
2+ 
Accumulation of C-terminal fragments causes Ca permeable channel formation. 
Extracellular C-terminal fragments form de novo ion channels. Influx of Ca^ "^  may 
lead to cell death. C-terminal fragments may attack mitochondria that release 
cytochrome c, causing programmed cell death. C-terminal fragments may induce 
inflammatory response, increasing the production of NO in microglia and astrocytes. 
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1.4 The role of proteases in amyloid precursor protein processing 
1.4.1 a-secretase and P-secretase 
a-secretase refers to enzyme(s) that cleaves Lysl6-Leul7 of Ap. Since it cleaves 
at the middle of Ap, this cleavage prevents Ap formation and produce 
non-amyloidogenic p3 peptide, a-secretase pathway represents the major pathway 
(>90%) occur in non-neuronal and neuronal tissues. By cloning expression, three 
membrane-bound proteases have been proposed to be the true candidate of esearcher 
discovered three a-secretases, known as the ADAM9, 10 and 17. Al l of them belong 
to a family of proteins possess disintegrin and protease activity known as "a 
disintegrin and metalloprotease" (ADAM), a family of proteins possess disintegrin 
and protease activity (17 out of 29 in all known ADAMs). They are transmembrane 
metalloproteases that share common catalytic motif, a typical HExxH zinc-binding 
motif (Black et al. 1998). 
AD A M I 7 is also called the tumor necrosis factor-a cleaving enzyme (TACE). 
As the name implied, TNF-a is one of its substrate (Moss et al. 1997). Other 
substrate includes TGF-a，L-selectin and APR It acts as a sheddase to cut both type I 
and type I I transmembrane proteins. There is evidence that TACE can cleave APP at 
a-secretase site in vitro and in vivo but not a preferred substrate as kcat/km is 100-fold 
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higher than TNF-a. Nevertheless, TACE is the major regulated a-secretase. 
Phorbol-ester increases the activity of TACE, which suggests that this a-secretase 
pathway is regulated by PKC activation (Buxbaum et al. 1998). For TACE double 
knockout mice, the mice died between E17.5 and postnatal D l , suggesting TACE has 
important physiological role. TACE -/- fibroblast obtained from TACE KO mice still 
have a-secretase activity indicated that TACE is not the sole a-secretase (Buxbaum et 
al. 1998). 
AD A M I 0 is also homologous to an enzyme called Kuzbanian in drosophila 
(Rooke et al. 1996). Like TACE, APP is not the only substrate of AD A M I 0. The 
main substrate is Notch and its ligand Delta, Jagged (Pan and Rubin, 1997). Other 
substrates include type IV collagen and ephrin-A2. Notch is a primary mediator of 
lateral inhibition in embryonic development (Pan and Rubin, 1997). Notch 
processing is remarkable similar to APP processing. The detailed comparison wi l l be 
discussed in "y-secretase" section. AD A M I 0 acts as constitutive a-secretase in 
PKC-independent manner (Lammich et al. 1999). AD A M I 0 double knockout mice 
are not viable and the defect is similar to Notch -/- mice. However, AD A M I 0 -/-
fibroblast still has preserved a-secretase activity (Hartmann et al. 2002) (even varies 
between clones). 
Unlike AD A M I 0 and 17，ADAM9 (also called Metalloprotease/Disintegrin/ 
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Cysteine-rich protein 9 or meltrin y) is not a major a-secretase except in brain nor 
cleave at traditional a-secretase site. ADAM9 cleaves at Hisl4-Glnl5 instead of 
Lysl6- Leu 17 of Ap. Any processing site within Ap that yields non-amyloidogenic 
fragment regard as a-secretase-like activity otherwise calls P-secretase-like activity 
(such as p，cleavage site of tyrosine 10-glutamatel 1 of Ap). The Hisl4-Glnl5 cutting 
site cleavage of Ap has been identified in primary cultures of rat hippocampus 
neuron, suggesting ADAM9 is one of the a-secretases in vivo (Simons et al. 1996). 
Co-expression of APP and ADAM9 in COS-7 also leads to an increase production of 
sAPPa. Surprisingly, there are no major abnormalities in ADAM9 double KO mice 
or any changes in concentration of sAPPa and sAPPp (Weskamp et al. 2002). This 
may be due to the fact that other members ofADAMs take over the role of ADAM9. 
Asai et al. (2003) applied siRNA technique to suppress the expression of 
ADAM9,10,17 in A172 human glioblastoma (more endogenous a-secretase activity), 
together with overexpression of 3 ADAMs in COS-7 cells, showing that all three 
proteases contribute similar extent in the a-secretase activity of APP. 
Given the fact the a-secretase pathway constitutes the non-amyloidogenic 
pathway; one major challenge to slow down the pathogenesis of AD is to upregulate 
the expression of a-secretase so as to divert the amyoidogenic pathway of APP. 
Interestingly, the cholinesterase inhibitors and muscarinic agonists that are found to 
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have mild therapeutic benefits on AD were found to increase sAPPa production via 
PKC-dependent pathway. Recent study on some non-steroidal anti-inflammatory 
drugs (NSAIDs) indicated that these drugs increase the activity of TACE (ADAM 17) 
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Fig 1-5 Similarity between APP processing and Notch processing 
a-secretases (ADAM 9，10, 17) or P-secretase cleave at APP, which is similar to 
ADAMIO processing of Notch. AD A M I 0 (KUZ) and ADAM17 (TACE) is the major 
a-secretase in non-neuronal cells. AD A M I 7 is regulated through PKC pathway while 
ADAMIO is a constitutive a-secretase. ADAM9 (MDC9) is a predominant 
a-secretase in hippocampal neurons. 
26 
P-secretase (also known as beta-site APP cleaving enzyme BACE) refers to the 
protease that cleaves at the N-terminal Ap from APP (i.e. the Met-1 and Asp+1 of Ap) 
(Fig 1-6). In 1999, four groups of scientists independently identified P-secretase 
(beta-site APP cleaving enzyme BACE) as a novel transmembrane aspartyl protease 
(Hussain et al. 1999; Sinha et al. 1999; Vassar et al. 1999; Yan et al. 1999). Another 
aspartyl protease as a homolog of BACE, designated as BACE2, was subsequently 
found (Farzan et al. 2000; Hussain et al. 2000). However, BACE2 cleaves other site 
of Ap in addition to the p-secretase cleavage site, thus raising the doubt for its role in 
Ap pathogensis. Moreover, expression of BACE2 does not correlate very well with 
the affected brain regions in AD. BACE2 is mainly expressed in vascular tissue such 
as heart, kidney and lungs while BACE is mainly expressed in brain and pancreas. 
The most compelling evidence for a physiological role of BACE came from 
study of BACE -/- knonckout mice. BACE -/- mice are viable and fertile with no 
major abnormalities found until 18 months. The lack of P-secretase in knockout mice 
was confirmed by the lack of detectable Ap and sAPPp in CSF and brain (Roberds et 
al. 2001). 
p-secretase may also have a role in immune response. The search of P-secretase 
substrate reveals that P-selectin glycoprotein ligand 1 (PSGL-1) (Lichtenthaler et al. 
2003) and a2,6-siaytransferase (ST6Gal I) (Kitazume et al. 2003) are the possible 
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substrates of BACE. PSGL-1 is a type I transmembrane protein that mediates 
leukocyte adhesion (to endothelial) in inflammatory reactions (eg. CD22 
redistribution). Like APP, PSGL-1 is cleaved by ADAM and BACE. BACE cleaves 
at NLfS ofPSGL-1, which is similar to NL tD of APPsw (Lichtenthaler et al. 2003). 
ST6Gal I is cleaved by BACE at TLfQ and the glutamine residue is removed by 
exopeptidase (Kitazume et al. 2003). Ectodomain shedding of single pass 
transmembrane is a general phenomenon that mediated by initial cleavage of 
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Fig 1-6 P-secretase cleavage of APP 
A small portion of APP is cleaved by p-secretase (BACE). A cytotoxic peptide, 
C-terminal 99 (C99) is released that causes apoptosis. 
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1.4.2 Y-secretase complex 
y-secretase refers to enzyme activity that cleaves at the C-terminal of A|3 to 
generate either Ap40 or Ap42. Unlike a- or P-secretases, y-secretase is a 
multi-protein complex, comprising at least four protein components. It has been 
known for a long time that presenilin (PS) is closely associated with the activities of 
y-secretase and the mutation of PS accounts for many cases of familial Alzheimer's 
disease (FAD) (Russo et al. 2000). By series of elegant experiments using 
co-immunoprecipitation, there is evidence that y-secretase comprises catalytic 
domain PS and at least threre co-factors nicastrin, APH-1 and PEN-2 (De Strooper 
2003). 
Two isoforms of presenilins (PSl and PS2) have been characterized that 
constitute the catalytic subunits of the y-secretase (Wolfe et al. 1999). PS holoprotein 
is a 50 kDa protein, predicted with eight transmembrane domains topology. PS is not 
glycosylated, sulfated, acetylated, or linked with glycosaminoglycan (DeStrooper et 
al. 1997). However, PS is phosphorylated (Seeger et al. 1997). PS is widely 
conserved in plants, invertebrates, and vertebrates but not in yeast. PS is cleaved 
between TM6 and TM7 by unknown presenilinase soon after synthesis (Thinakaran 
et al. 1996) to produce PS-NTF (30 kDa) and PS-CTF (20 kDa). PS holoprotein wi l l 
be rapidly degraded i f not cleaved by presenilinase (Thinakaran et al. 1996). Two 
30 
invariant aspartate residues (D257 and D385 ofPSl) located on TM6 and TM7 were 
found to be essential to y-secretase activity (Wolfe et al. 1999) thus raising the 
possibility that PS is the catalytic core of y-secretase. PSl -/- (E17) and PSl -/- PS2 
-/- (E9.5) knockout mice died in utero, with somite segmentation defects (similar to 
Notch 1 KO) (Shen et al. 1997). PS2 -/- knockout mice are however viable. Presenilin 
also has other functions beside protease. The large hydrophilic loop of PS can bind 
GSK3P (Takashima et al. 1998) and P-catenin (Nishimura et al. 1999), trafficking 
proximal to tau. PS also bridges between centrosome and kinetochore in M-phase 
arrested HEK293 cells, arresting cell division i f both PSl PS2 antisense nucleotides 
added (Jeong et al. 2000). In addition, PS is required for normal functions of 
synapses as for correct transport of NMD A receptors (Saura et al. 2004). 
There are many protein factors that recently found to form complex with PS that 
contributes to the normal functions of PS. Nicastrin forms a large complex with PS 
(Yu et al. 2000). Loss of function of nicrastin leads to a reduction in Ap production 
and a massive accumulation of the C-terminal fragments of the beta-amyloid 
precursor protein, indicating an involvement in y-secretase activity (Edbauer et al. 
2002). 
The other two new members of y-secretase complex, anterior 
pharynx-defective-1 (APH-1) and presenilin enhancer-2 (PEN-2) were discovered 
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through a genetic screen in C. elegans (Francis et al. 2002). APH-1 was first 
discovered in C. elegans as the membrane bound protein that may have a role in the 
maturation of PS/nicastrin (NCT) complex (Gu et al. 2003). APH-1 is a 30 kDa 
protein with typical seven transmembrane domains topology (Fortna et al. 2004). 
APH-1 has two isoforms, differ at very C-terminus region (Goutte et al. 2002). 
APH-1 associates with NCT soon after synthesis (Fortna et al. 2004). APH-1 
interacts with mature and immature forms of presenilins and nicastrin and may play a 
role in maturation of presenilin. nicastrin complexes. Likewise, PEN-2 is a small (12 
kDa) double-pass transmembrane protein (Steiner et al. 2002). The loss of fiinction 
of PEN-2 results in accumulation of PS holoprotein. APH-1 and PEN-2 interacts 
strongly with presenilin and nicastrin and is required for the activity and 
accumulation of y-secretase (Francis et al. 2002). y-secretase complex is active only 
when all four members are present and PS is in heterotetramer in a ratio of PS (50 
kDa):NCT(130 kDa):APH-l(30 kDa):PEN-2(10 kDa) agrees the molecular weight of 
y-secretase around 200-250 kDa by co-immunopreciptation using mild detergent 
extraction method (Kimberly et al. 2003). 
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Fig 1-7 Assembly of y-secretase complex 
APH-1 acts as scaffold protein to assemble y-secretase complex. Glycosylated 
nicastrin (NCT) stabilizes presenilin (PS) and APH-1. PEN-2 stabilizes pre-complex 
and facilitate PS endoproteolysis between transmembrane domain 6 and 7. The 
whole complex is tightly regulated. Once the length of ectodomain is shorter than 
200-300 residues, it wil l be cleaved by y-secretase complex. 
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Recent study indicate that y-secretase belongs to a large groups of 
intramembrane proteases involved in regulated intramembrane proteolysis (RIP), a 
widely conserved protease systems for controlling various biological processes 
(Weihofen et al. 2003) (Fig 1-8). Four representative families have been identified; 
presenilins (7-secretase), site-2 protease, rhomboid and signal peptide peptidase. 
Presenilin and signal peptide peptidase are aspartyl proteases (Weihofen et al. 2002). 
Site-2 protease belongs to metalloprotease family (Rawson et al. 1997) while 
rhomboid is a serine protease (Urban et al. 2001). y-secretase and rhomboid cleave 
only type I proteins. On the other hand, site-2 protease and signal peptide peptidase 
only cleave type I I proteins. Interestingly, all four proteases participate in signaling. 
Y-secretase takes a major role in Notch signaling (DeStrooper et al. 1999) and second 
messenger signaling (Gao et al. 2001). Site-2 protease controls cholesterol synthesis 
by processing SREBP (sterol response element binding protein) (Nohturflft et al. 
1999, 2000). Rhomboids truncate EGF ligands (Spitz, Keren, Gurken) thus 
controlling EGF signaling (Lee et al. 2001). Signal peptide peptidase cleaves signal 
peptide o fMHC I after processing by signal peptidase, involving in HLA-E signaling 
(Lemberg et al. 2001). 
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Fig 1-8 Families of intramembrane protease 
The conserved motif embedded in hydrophobic transmembrane sequence. 
PS-dependent y-secretase and Rhomboids only cleave type I proteins while site-2 
protease and SPP only cleave type I I proteins. PS and SPP are aspartyl protease with 
conserved motifs. Site-2 protease is a zinc metalloprotease and rhomboid is a serine 
protease. Intramembrane proteolysis occurs in different groups of protease. 
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APP processing is remarkable similar to the Notch processing, the cleavage site 
mediated by y-secretase after ectodomain shedding is not identical. The y cleavage 
site is located in the middle of transmembrane domain while S3 cleavage site is 
located near C-terminus of transmembrane domain. This leads to the speculation that 
APP also has "S3" processing site. Sastre et al. (2001) reported the presence of this 
new processing site, called s-cleavage site (5-cleavage site is Ap -11 that 
predominately found in hippocampus neurons). 8 cleavage site starts at Ap 49/50 
(Sastre et al. 2001 and Sato et al. 2003), which is near the C-terminus of 
transmembrane domain. The CTFa (C83) / CTFp (C99), which has transmembrane 
domain and CTFy (C59/57) was found in PlOO fraction. However, CTFe (C50) 
discovered as soluble (SI00) form, representing true APP intracellular domain 
(AICD) (Sastre et al. 2001). As for CTFy, the production of CTFs is completely 
abolished in PSl -/- PS2 -/- fibroblasts. Again, Edbauer et al. (2003) reported CTFa / 
CTFp cleaved twice in the recombinant y-secretase complex in yeast. The processing 
in this heterologous system agrees with previous studies (Sastre et al. 2001; Sato et al, 
2003; Walsh et al, 2003). 
1.4.3 Caspases 
Caspases are a group of cysteine proteases cleaving subset of cellular 
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polypeptides at Asp-X bonds (Nicholson and Thomberry 1997). There are four 
groups of caspase: initiator caspase, effector caspase, inflammatory caspase and 
development caspase. Caspase recognizes tetrapeptide whereas aspartate residue at 
PI is an absolute requirement and residue at P4 is the specificity determinant. The 
dormant proenzyme will become active when stimulating by apoptotic signal. 
Caspase -3 is an effector caspase that promotes cell death. 
There is evidence that caspase-3 is responsible for the processing of APP 
(Gervais et al. 1999). During apoptosis, APP is efficiently processed by various 
caspases, resulting in an increase in Ap formation. Caspase-3 is the dominant caspase 
in APP processing, mediating the proteolysis at the cytoplasmic tail of APP. One of 
the APP processing products, the 3.5 kDa truncation product of the C-terminal 
fragment of APP known as APP-C31, is shown to be cleaved by caspase-3. APP-C31 
is cytotoxic to neurons in primary cultures (Galvan et al. 2002), suggesting that 
caspase-3 mediated APP processing may play role in neuronal cell death.. 
1.4.4 Kallikrein-like proteases 
The members of kallikrein family are a group of serine proteases that are 
involved in generating small bioactive peptides from high molecular weight 
precursor. Until recently, three kallikreins have been identified and characterized, 
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known as pancreatic kallikrein (KLKl) , glandular kallikrein (KLK2) and 
prostate-specific antigen protein (KLK3/PSA). Now there are 15 members identified 
based on their structural similarity and gene location. Al l members are serine 
proteases and located on chromosome 19ql3.3-13.4 (Gan et al. 2000). Al l kallikrein 
genes share similar homologies in genomic and protein level. Besides, steroid 
hormones regulate the expression level of kallikrein members (Yousef et a l l 999). 
Kallikrein 6 was first reported by Anisowicz et al. (1996) who cloned KLK6 
(named protease M) by differential display, based on significant differences in 
expression between normal and malignant breast cancer. Yamashiro et al. (1997) 
cloned the gene from human colon adenocarcinoma cell line COLO 201 and found 
highest expression level in brain by northern blot, hence named neurosin. These two 
proteases are later shown to be the identical protease. The participation of KLK6 in 
APP processing was reported by Little et al. (1997) in co-transfection of APP and 
KLK6 to HEK293 cells. KLK6 may play a role in development and progression of 
AD. Rodent homologs of KLK6 have been identified (Matsui et al. 2000; Scarisbrick 
et al. 1997), known as mouse brain serine protease (mBSP) and rat 
myelencephalon-specific protease (MSP). 
Neurosin is expressed in many tissues, including breast, brain, spinal cord, 
kidney, uterus, salivary gland, thymus, spleen and testis (Petraki et al. 2001) Strong 
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and diffuse positive staining was observed in the epithelium of the choroid plexus, 
consisting with a previous finding that neurosin is secreted in cerebrospinal fluid 
(CSF) (Diamandis et al. 2000). The epithelium of breast, genitourinary tract, 
gastrointestinal tract and salivary glands also stained positive. Taken together, 
neuroendocrine cells in several organs expressed neurosin. Thus it may be used as 
biomarker of diseases (eg, AD or breast / ovarian cancers). In brain, neurosin is 
mainly expressed in whiter matter of corpus callosum, medulla oblongata and spinal 
cord (Scarisbrick et al. 2001). All these regions associated with oligodendroglia. 
Neurosin immunoreactivity is also observed in Schwann cells of peripheral nervous 
system. Similar results were obtained in mouse (Matsui et el., 2000). 
The expression level of neurosin is different from AD/PD patients compared to 
normal subjects. In the hippocampus of AD patients, neurosin immunostaining was 
visible in all neuronal components. In addition, neurofibrillary tangles and senile 
plaques but not intracellular tangles were positively stained with neurosin antibody 
(Ogawa et al. 2000). In PD brain, neurosin-positive staining observed in Lewy bodies 
(Ogawa et al. 2000). Neurosin may participate in degradation and removal of tangles, 
plaques and Lewy bodies (Matsui et al. 2000). 
KLK6 is expressed at high levels in inflammatory cells of active demyelination 
in human multiple sclerosis lesions (Scarisbrick et al. 2002) Neurosin may 
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participate in the breakdown of myelin debris. Neurosin degrades myelin basic 
protein (MBP) and myelin oligodendrocyte glycoprotein (oMOG). Neurosin appears 
to facilitate trans-endothelial migration of inflammatory cells to CNS. The potential 
role of neurosin in inflammatory cells is further supported by the presence of other 
neutral proteases such as matrix metalloproteinase (Leppert et al. 1996; Stuve et al. 
1996) and tissue plaminogen activator in inflammatory site. The attenuation of CNS 
inflammatory disease achieve by blockage of myelin degradation by anti-neurosin 
antibody in multiple sclerosis mice (Blaber et al. 2004). This is because neurosin 
hydrolyses extracellular matrix proteins to participate immune cell trafficking. 
The correlation between neurosin and AD is also supported by clinical studies. 
The concentration of neurosin in tissue extract decreases by half in AD brain while 
increases three fold in cerebrospinal fluid (Diamandis et al. 2000). However, the 
relation between them is not known because neurosin in CSF is mainly in pro-form 
rather than the active form (Okui et al. 2001). 
1.5 Obj ective of the present study 
In this study, the role of neurosin was investigated to evaulate its role in APP 
processing. In the first part of the thesis, the human neurosin was cloned and effort 
was made to produce functional recombinant neurosin for characterizaton. The effect 
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of co-expression of various molecular chaperones to improve recombinant protein 
solubility in the cytosol was investigated. In the second part of the thesis, a APP 
expression cell model in APP-deficient neuroblastoma B103 was establised in order 
to facilate the study of the role of protease in APP processing. Human APP cDNAws 
cloned and transfected to B103 for immunoblot analysis. 
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Chapter 2 Materials and Methods 
2.1 Experimental procedure 
2.1.1 Plasmid construction 
To clone APP gene and neurosin gene, hippocampus and SH-SY5Y cDNA were 
used as template respectively. The cDNAs of hippocampus and SH-SY5Y cells were 
made by reverse transcription of total RNA. Hippocampus RNA was purchased from 
Clontech and SH-SY5Y RNA was extracted from the cells by the TRIzol (Invitrogen) 
reagent and purified by ethanol precipitation. For reverse transcription, Superscript I I 
(MMLV reverse transcriptase from Invitrogen) was used to produce complementary 
DNA according to the instructuions of the manufacturer's protocol . 
APP (NCBI accession number NM一000484) was cloned from hippocampus 
cDNA followed this condition: 95。C 5 minutes for initial activation, 95°C 45 seconds 
for denaturation, 55°C 30 seconds for annealing, 68。C 2 minutes and 20 seconds for 
extension by PfU polymerase (repeated 20 cycles for denaturation, annealing and 
extension steps) and 68。C 10 minutes for final extension, using primers NM484-91F 
and NM484-2534R. 1 j i 1 mixture was used as template in the second round PCR 
(nested PCR) and the condition was the same, except that primers NM484-131F and 
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NM484-2463R were used. Neurosin (KLK6, NCBI accession number 
D78203/NM_002774) was cloned from SH-SY5Y cDNA using XM5658_219F and 
XM5658_964R as primers. The PGR condition was as follow: 95。C 5 minutes for 
initial activation, 95。C 30 seconds for denaturation, 60°C 30 seconds for annealing, 
68°C 45 seconds for extension by Pfu polymerase (repeat 35 cycles for denaturation, 
annealing and extension steps) and 68。C 10 minutes for final extension. 
APP gene was ligated to pCR2.1-T0P0 and neurosin was ligated to 
pCR4-T0P0 by the TOPO cloning method according to manufacturer's protocol. 
Ligated vectors were then transformed to E. coli to prepare plasmid. Again, 
APP/pCR4-T0P0 and neurosin/pCR2.1-TOPO were used as template to introduce 
restriction enzyme cleaving site by linkers of primers using PGR. APP was ligated to 
pcDNA3, pCMV-Tagl and pEGFP-Nl in Hind I I I / Sal I sites. Neurosin was ligated 
to pcDNA3 and pRSET A in Bgl I I / Xho I sites. A series of truncated forms APP 
(C99, C83, C59, C57, C50, C31) were also amplified the same way using 
APP/pCR4-T0P0 as template. The forward primer (e.g. C99_HIND3) and reverse 
primer APP GC SALIR were used. The PGR condition was the same except the 
extension time is shorten to 1 minute per cycle. The amplified fragments were 
digested by Hind I I I and Sal I and then subcloned to pEGFP-Nl linearized with Hind 
Ill/Sal I double digestion. 
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2.1.2 DNA purification, ligation and restriction enzyme digestion 
After PCR reaction, the PCR products were separated by agarose gel 
electrophoresis and visualized by ethidium bromide pre-stained 1% (w/v) agarose gel. 
Agarose gel was prepared by weighing 1% (w/v) agarose dissolved in TAE 
electrophoresis running buffer. Agarose was dissolved in TAE by boiling using 
microwave. The agarose gel was then cool down to solidify. DNA samples were 
dissolved in 6X buffer (bromophenol blue and 30% glycerol) and allowed to run at 
constant voltage (120V) for 30 minutes. The bands visualized under UV illuminator 
were excised. QIAgen kit was used to extract DNA. This protocol was based on 
manufacturer's protocol with some modifications. The DNA excised in small pieces 
was dissolved in QG buffer with frequent vortex at SOT, The DNA in dissolved 
buffer was then applied to a small column supplied by the kit and centrifuged at 
maximum speed for 1 minute. DNA was bound to the small column. An amount of 
0.75 ml wash buffer was added to the column. After incubation for 5 minutes, the 
column was spun for 1 minute to remove the wash buffer. I f necessary, the washing 
procedure could be repeated once. Finally the bound DNA was eluted by adding 50 
|il elute buffer (10 mM TrisCl, pH 8) to the column. After 1 minute of incubation, the 
column was centrifuged for 1 minute. The resulting eluate was collected. The 
concentration of DNA determined by determined by spectrometry and ready for 
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sub cloning 
For restriction enzyme digestion, lOX enzyme buffer, lOOX BSA and restriction 
endonuclease were added in a microfuge tube containing DNA according to the 
protocols of New England Biolabs (NEB). The DNA fragment was digested 
overnight and gel-purified for ligation. For ligation, T4 DNA ligase buffer, digested 
DNA PGR products, digested vector and T4 DNA ligase were added to the tube and 
incubated at 16°C overnight. Usually, the final reaction volume was 10|j,l. The 
amount of DNA product and vector was in the molar ration of 3:1 to maximize the 
ligation efficiency. 
2.1.3 Competent cell preparation 
The competent cells were prepared by the calcium chloride method. The 
positive colony was picked and transferred to 100 ml fresh LB. The absorbance (at 
600 nm) of the culture monitored regularly until the OD reached 0.6. The cells were 
now in mid-log phase that were suitable for competent cell preparation. The culture 
was transferred to a sterilized ice-cold polypropylene tube. The culture was 
centrifuged for 10 minutes at 4°C to pellet the cells and then resuspended in 10 ml 
O.IM CaCb. This procedure was repeated one more time and the pellet was finally 
resuspended in 60mM CaCb with 15% glycerol. The culture was aliquoted lOOpl per 
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tube and stored in -70°C refrigerator for further use. Similarly, the transformed 
competent cells were used to transform the expression plasmid KLK6/pRSET A so 
that the host cells could express both chaperone proteins and recombinant proteins. 
The chaperone plasmid and expression plasmid could not be co-transformed in single 
process because the transformation efficiency was too low. 
2.1.4 Transformation 
The plasmid was transformed to Kcoli and the positive clone was selected by 
appropriate antibiotics. An amount of 1 to 10 |il (0.1 |ig/ul) ligated vector was added 
to the competent cells and mixed thoroughly. The tube was incubated in ice for 30 
minutes, to allow DNA adsorb on the surface of E. coli. After that, the tube was 
transferred to 42°C water bath for exactly 90 seconds. The tube was cooled down for 
2 minutes and 0.4 ml LB medium was added to the tube. The tube was then 
incubated at 37°C for 45 minutes, to allow the cells produce antibiotic-resistant 
enzymes. The cells were spread on LB agar plate (with appropriate antibiotics) by a 
sterile spreader. The plate was incubated at 37。C overnight and colonies were picked 
the next day. 
2.1.5 Plasmid miniprep 
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A single colony of bacteria was picked and inoculated in 3 ml LB medium with 
appropriate antibiotics and allowed them to grow overnight. The cells harvested by 
centrifuge at maximum speed for one minute. The supernatant was discarded 
completely and re-suspended in 100 solution I. It was followed by the addition of 
200^1 solution I I (1% SDS, 0.2M NaOH), and then mixed by inverting the tube five 
times. The mixture was incubated on ice for 5 minutes. An amount of 150|xl solution 
I I I (3M Na acetate, pH 5.2) was added and mixed thoroughly by inverting the tube 5 
times. The mixture was further incubated on ice for 5 minutes; the tube was 
centrifuged for 15 minutes at maximum speed (12,000 rpm). The supernatant 
containing DNA was transferred to another tube for further purification. Equal 
volume of buffer-saturated phenol chloroform was added to the supernatant. The 
mixture was vortexed for 5 minutes and centrifuged for another 5 minutes to separate 
aqueous phase and organic phase. Two-third volume of the aqueous phase that 
contained plasmid DNA was aspirated and transferred to another tube. An amount of 
1/10 volume of solution I I I and 2 volume absolute ethanol were added to the aqueous 
phase to precipitate plasmid DNA at -20。C. Precipitated plasmid DNA was pelleted 
by centrifuging for 5 minutes and washed by 70% ethanol once. The plasmid DNA 
was dried in room temperature and dissolved in 1/1 OX TE buffer. The plasmid DNA 
was ready for later use, such as subcloning or transfection. 
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2.1.6 Prokaryotic expression of neurosin 
For small-scale protein expression, KLK6/pRSET A was transformed to Kcoli 
strains (BL21 or C41) for optimized expression. The clone was selected by 100 ng/jxl 
amplicllin (to select pRSET A) and 35|ig/|il chloramphenicol (in case where 
ACYC184 plasmids such as pLysS or pG-KJE6 were co-transformed) and inoculated 
in 2 ml LB medium. The growth rate of E.coli was monitored by spectrophotometry 
until the culture reached the mid-log phase (OD600 = 0.4 - 0.6). One ml of culture 
was taken out, centrifuged and the cell pellet was dissolved in 1% SDS for analysis. 
The total lysate was boiled for 5 minutes to denature the proteins. 
For large-scale protein expression, the transformed clone was inoculated in 3 ml 
LB medium overnight and 200|il culture was transferred to 200 ml fresh LB medium 
with appropriate antibiotics. For protein expression, 1 |ig plasmid DNA was 
transformed in C41, Tuner, Origami or BL21. A single colony was picked in the 
following day and inoculated in 10 ml LB medium with 100 |xg/ml amplicllin and 34 
jig/ml chloramphenicol. The neurosin expression plasmid was selected by 100 |ig/ml 
amplicllin while chloramphenicol was used to select pACYC-based chaperone 
plasmids (pLysS or molecular chaperone plasmid). I m M IPTG was added to the 
culture in mid-log phase (OD600 = 0.6) in induce neurosin expression. Molecular 
chaperone expression was induced by either 0.5 ng/ml tetracycline and/or 1 mg/ml 
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L-arabinose. Unless otherwise specified, the culture was induced for 3 hours before 
harvesting for protein purification. As mentioned above, the culture was allowed to 
grow until mid-log phase and protein expression was induced with IPTG for 
appropriate hours. The cells were harvested (4000 rpm, 15 min, 4°C) and 
resuspended in binding buffer (5 ml per 100 ml culture). The binding buffer 
contained 5 mM imidazole in Tris-saline buffer. The suspension was sonicated (90W) 
on ice for 5 minutes. To separate the soluble and from insoluble materials, the 
suspension was centrifuged at 30,000 x g for 30 minutes at 4°C. The resulting 
supernatant was saved for metal chromatography. The pellet was then washed with 
fresh binding buffer and centrifuged at 30,000 x g for another 15 minutes at 4。C. The 
insoluble materials, which contained the inclusion bodies, were resuspended in same 
volume of binding buffer and the proteins in both fractions were analyzed by 
SDS-PAGE. 
2.1.7 SDS-PAGE 
SDS-PAGE was carried out according to the Laemilli's method. To prepare 
resolving gel, 0.375M TrisCl pH8.8，0.1% SDS, 0.05% APS and 0.01% TEMED 
were added to the gel mixture. Various concentrations of 29% (w/v) acrylamide / 
0.8% bis-acrylamide was added to final concentration of 7.5%, 10%, 12% or 15%, 
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depending on the separation of target proteins. The gel mixture was then added 
between the glasses of gel cassette and overlaid with water-saturated butan-l-ol. The 
stacking gel was prepared by mixing 0.125M TrisCl pH 6.8, 0.1% SDS, 0.05% APS, 
0.01% TEMED and 5% acrylamide (all are final concentration). The stacking gel 
solution was then added to the cassette and the comb was put in polymerizing gel. 
Protein samples were boiled in sample buffer containing Tris-Cl pH 6.8，glycerol, 
SDS, DTT and bromophenol blue, for 5 minutes. 
2.1.8 Protein sample preparation 
The BCA protein assay kit (Pierce) was used for protein concentration 
determination. Bovine serum albumin (BSA) dissolved in RJPA was used as 
standards, ranging from 1.5 mg/ml to 4.5 mg/ml at 0.5 mg/ml interval. An amount of 
10 |il standards and samples were added to the wells of microtiter plates (NUNC). 
After that, 50 volumes solution A was mixed with 1 volume solution B and 100 |il of 
the mixture were added to the samples (1:10). The protein assay performed after 30 
minute incubnation at 37°C. The absorbance was measured at 562 nm by [iQuant 
spectrophotometer (Molecular Device, USA). In general, about 50 [ig protein sample 
was added to each well for SDS-PAGE and immunoblot. 
The protein samples were prepared in RIPA (radioimmunoprecipitation assay) 
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lysis buffer. The cells were washed in PBS once and then scraped by rubber 
policeman. The cells were harvested by centrifugation at maximum speed for 1 
minute. The buffer was aspirated and the cells were lysed with 48 \i\ RIPA lysis 
buffer and 2 ^il 25X Complete protease inhibitor (Roche). The cells were 
homogenized by vortex for 5 minutes at 4°C, followed by centrifugation for 15 
minutes at 4°C to remove the cell debris. An aliquot of 10 \i\ samples were used for 
BCA protein assay. 
2.1.9 Western Blot 
For immunoblot, PVDF (Millipore) membrane (0.45|im) was soaked in absolute 
ethanol and immersed in Towbin transfer buffer (with 20% EtOH). After 
electrophoresis, the polyacrylamide gel was transferred to transfer buffer to allow 
equilibration for 15 minutes. To transfer proteins from gel to membrane, three 3 mm 
filter papers (8.5 cm x 5.0 cm) were immersed in transfer buffer and then placed 
them on the transfer unit. The equilibrated gel was laid down on the filter papers and 
PVDF membrane was then put on the top of the gel. Three filter papers again were 
placed on the top of the PVDF membrane. A test tube is rolled on the stack to remove 
air bubbles. The transfer unit was run at constant voltage (15 V) for 90 minutes. 
After the transfer, the membrane was re-soaked in absolute ethanol, followed by 
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rinses in distilled water. To minimize non-specific binding of antibody, the PVDF 
membrane was pre-incubated in the blocking buffer (5% non-fat dry milk (Nestle) 
and 1% BSA (Sigma) in Tris-buffered saline-Tween 20 (TBS-T)) for 2 hours at room 
temperature. Primary antibodies were then added to the blocking buffer and 
incubated overnight at 4。C. It should be noted that the concentration of primary 
antibody varied from case to case, usually in 1:2000 or 1:5000. The membrane was 
washed three times in TBS-T, 5 minutes each. Finally, the membrane was incubated 
in horseradish (HRP)-conjugated secondary antibodies (Zymed or Santa Cruz) in 
1:5000 in blocking buffer for 2 hours at room temperature. The membrane was then 
washed three times as previously described. 
The immunoreactive protein bands in the blot were visualized by the ECL 
detection kit (Amersham). For signal detection, the solution 1 of the kit was mixed 
with solution 2 of the kit. The solution was added to the membrane that was placed 
on a piece of Gr ad wrap. After 1-minute incubation, the excess solution was removed 
by blotting paper. The membrane was then covered with another piece of plastic 
Gradwrap and then placed in the X-ray film cassette on top of an X-ray film. The 
fi lm was usually exposed to the membrane for 5 to 15 minutes. I f necessary, the 
membrane could be stripped and re-probed with other antibodies. 
The probes bound to the PVDF membrane could be stripped off by lowering the 
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pH of the stripping solution. After ECL detection, the antibodies were removed by 
stripping solution (25 mM glycine pH 2, 1% SDS) by incubating at room 
temperature for 30 minutes. The membrane is re-activated in absolute ethanol and 
then blocked by 5% non-fat dry milk / 1% BSAas previously mentioned. 
2.1.10 Immobilized metal affinity chromatography 
The recombinant neurosin were produced as a fusion protein with polyhistidine 
tag, which could be purified by metal chelation affinity chromatography under native 
or denatured conditions. Novagen His-Bind resin was used for purification according 
to manufacturer's protocol with modifications. For resin preparation, 1 ml of resin 
was applied to the column and allowed the resin settle down. The resin was washed 
with 3 volumes distilled water (3 ml) and then charged with metal ions by washing 
with 5 volumes charged buffer, which is composed of NiS04. Ni binds to the 
immobilized resin. The protein sample dissolved in binding buffer was filtered 
through 0.45 jim membrane to remove particulates and then added to the column. The 
resin was washed with ten volumes of binding buffer to remove the unbound proteins. 
To further remove protein impuries, six volumes of wash buffer containing 60mM 
imidazole was added to the column. The his-tagged neurosin was finally eluted in 
buffer containing 500 mM imidazole, which was collected in 1-ml fractions. The 
53 
resin could be re-generated by washing with strip buffer (that contains EDTA). The 
resin was the washed extensively with distilled water and stored in 20% ethanol at 
4°C to prevent flingi contamination. 
2.1.11 Enzyme assay 
Synthetic serine protease substrates Arg-Val-Arg-Arg-AMC (RVRR-AMC) 
(Bachem), Glu-Lys-Lys-AMC (EKK-AMC) (Bachem) and Phe-Val-Arg-AMC 
(FVR-AMC) (Calbiochem) and 7-amino-4-methylcoumarin (AMC) (Bachem) were 
made in DMSO to a final concentration of 1 mg/ml and stored at -20°C. Five ^il 
flurogenic substrate was mixed with equal volume trypsin or neurosin (1 mg/ml) and 
diluted in 90 assay buffer (50 mM Tris pH 7.4’ O.IM NaCl, 0.2% BSA). The 
reaction mixtures (100 ^il) in 96-microtiter plates (Costar) were incubated in a 
humidified chamber at 37。C overnight. Fluorescence was measured on Geminix 
micotiter plate reader (Molecular device) with an excitation at 355 nm and 460 nm 
for emission. Al l treatments were done in triplicate. 
2.1.12 Cell culture and transfection 
PC 12 or B103 cells were routinely maintained in 10 ml medium in T-75 flask 
(Iwaki). For cell passages, the cells were rinsed three times in phosphate-buffered 
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saline (PBS) to remove dead cells or debris and fresh medium was added to the flask. 
The cells were resuspended in 5 ml fresh medium by shaking and transferred to a 
50-ml conical tube (Falcon, BD Bioscience). The cells were pelleted by 
centrifugation at 1,000 rpm for 5 minutes. The medium was aspirated and 5 ml 
medium was added to resuspended the cells. One ml of cells in the medium was 
passed to the new T-75 flask, followd by the addition of 9 ml fresh medium. The 
cells left in the tube were used for seeding plates. The 12-well plates (Nunc) were 
used for immunoblot. To assess cell viablility, 10 |il cells mixed with equal volume 
trypan blue and an aliqut (10 |il) was added to the hemacytometer (Sigma) for 
counting cell numbers. To estimate the density of the cells, the following equation is 
used: N X 2 X 104 (N is the number of cells, 2 is the dilution factor of trypan blue, lO* 
is the dilution factor of the volume of the box in hemacytometer). The concentration 
of cells was adjusted to 1.2 x 10^ /ml/well and dispensed in 1 ml/well. 
Plasmid DNA was routinely transfected to mammalian cells by cationic lipid 
transfection methods. For PC 12 cells, 1 |ig plasmid was diluted in 100 ^il DMEM and 
mixed with 3 |il Cellfectin (Invitrogen) (1:3). The mixture was incubated at room 
temperature for 45 minutes to allow formation of DNA-liposome complex. The 
transfection medium was further diluted to 500 |aJ with DMEM. The culture media of 
the cells were aspirated and replaced by transfection medium and incubated for 6 
55 
hours, followed by the addition of 500 |il 10% FBS/DMEM to replace the transfected 
media. For B103 cells, 1 |ig diluted in DMEM and 2.5 ^il Lipofectamine 2000 
(Invitrogen) diluted in DMEM. The mixture was incubated for 20 minutes to allow 
DNA-liposome complex formation. After that, 500 |il of 10% FBS/DMEM was 
mixed with the transfection mixture and then added to the culture for 6 hours, 
followed by the replacement of fresh culture media. FBS was included during the 
transfection step because B103 cells could not survive in FBS-deficient medium. 
2.1.13 Live cell imaging 
For cell imaging, cells were seeded on coverslips placed in 12-well culture 
dishes. After treating the cells, the cells on the coverslip were then mounted onto a 
perfusion chamber with 100 ^il DMEM containing 10% FBS / 5% HS. No perfusion 
flow and heat was applied to the chamber because the experiments were usually 
carried out within short period of time. To capture confocal images, an argon-krypton 
laser was used with FITC filter set at 488 nm for viewing GFP fluorescent signals in 
an inverted confocal miscrope (Leica). The objective lens was set to 63x (water lens), 
captured the images accumulated 32 times. 
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2.2 Materials 
Ammonium persulfate, 10% (w/v) water to a final volume of IL. 
ammonium persulfate Ig Autoclave and store at room temp, 
distilled water to 10ml 
Store at 4°C. Sodium acetate, 3M (Solution III) 
Sodium acetate*3H20 40.8g 
Bromophenol blue, 10% (w/v) Distilled water 80ml 
Bromophenol blue Ig Adjust to desired pH with glacial acetic 
Distilled water to 10ml acid (pH 5.2) 
Store at room temperature. Add water to a final volume of 100ml, 
autoclave and store at room temperature. 
Ethidium bromide (EtBr), lOmg/ml 
Ethidium bromide 0.2g Sodium dodecyl sulfate (SDS), 10% (w/v) 
Distilled water 19.8ml SDS lOOg 
Store at room temperature and prevent Distilled water 800ml 
exposure to light. Warm the solution to 50°C to dissolve. 
Add water to a final volume to IL. 
Gel-loading buffer, DNA 
Sucrose 4g Sodium hydroxide (NaOH), lOM 
Bromophenol blue 0.025g NaOH 40g 
Distilled water 10ml Distilled water 100ml 
Store at 4°C. Store in a plastic container at room 
temperature. 
Isopropyl-p-D-thiogaiactopyranoside 
(IPTG), lOOmM TAE buffer, SOX 
IPTG 238mg Tris base 242g 
Sterile water 10ml Sodium acetate*3H20 136. Ig 
Filter sterilize using 0.22|Lim filter. NaaEDTA.SHjO 19g 
Store in 1ml aliquots at -20°C. Distilled water 700ml 
Adjust pH to 7.2 with acetic acid. 
Phosphate-buffered saline (PBS) Add water to a final volume of IL. 
NaCl 8g 
KCl 0.2g Tris-Cl, 2M, pH7.4 
Na2HP04 1.44g Tris base 242.2g 
KH2PO4 0.24g Distilled water 700ml 
Distilled water 900ml Adjust the pH by concentrated HCl. 
Adjust pH to 7.4 with IM HCl and add Add water to a final volume of IL. 
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Autoclave and store at room temp 
Coomassie Blue Stain 
LB broth Coomassie Blue 0.05% 
Tryptone lOg Acetic Acid 10% 
Yeast Extract 5g Methanol 40% 
NaCl 5g Distilled water 50% 
Distilled Water to IL 
Sterilize by autoclave. 6X Protein Sample Buffer, 8ml 
Upper buffer 7ml 
LB Agar Glycerol 3ml 
Tryptone lOg SDS Ig 
Yeast Extract 5g DTT 0.93g 
NaCl 5g Bromophenol blue 1.2mg 
Agar 15g Distilled water to 10 ml 
Distilled Water to IL 
Sterilize by autoclave, cool down and pour Enzyme assay buffer 
into culture dish. TrisCl pH 7.4 50mM 
NaCl O.IM 
30:0.8 Acrylamide Solution BSA 0.2% (w/v) 
Acrylamide 30g 
Bis-acrylamide 0.8g GTE Buffer (Solution I) 
Distilled water to 100ml Glucose 50mM 
TrisCl pH 8 25mM 
Upper Buffer TrisCl, pH 6.8 EDTA lOmM 
Tris Base 6g Filter sterilize and store at 4°C 
Distilled water to 100ml 
Adjust the pH to 6.8 by HCl 0.2M NaOH 11% SDS (Solution II) 
NaOH 0.2M 
Lower Buffer TrisCl, pH 8.8 SDS 1% (w/v) 
Tris Base 18.15g 
Distilled water to 100ml TE Buffer, pH 8 
Adjust the pH to 8.8 by HCl. TrisCl pH 8 lOmM 
EDTApH 8 ImM 
SDS Electrode Buffer, 5X 
Tris Base 6g Tris-buffered saline 
Glycine 28.8g TrisCl pH 7.4 lOOmM 
SDS, 10% 10ml NaCl 150mM 
Distilled water mix up to 100ml Sterilize by autoclave. 
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Tris base 80mM 
Western Blot Strip Solution EDTA 40mM 
Glycine pH 2 25mM 
SDS 0.1% (w/v) Charge buffer, 8X 
NiS04 400mM 
RIPA lysis buffer 
Triton X-100 1% (v/v) BLOTTO blocking buffer 
NaCl 150mM Tris-buffered saline IX 
TrisCl pH 7.4 50mM Non-fat dry milk 5% (w/v) 
Sodium deoxycholate 0.5% (w/v) Tween 20 0.05% 
Omit dry milk in western blot washing 
Semi-dry Transfer buffer, lOX buffer 
SDS 1.9g 
Tris base 29. Ig 
Glycine 14.7g 
Distilled water to 400ml 




Tris base 160mM 
Imidazole 40mM 
Adjust pH to 7.9 
Wash buffer, 8X 
NaCl 4M 
Tris base 160mM 
Imidazole 480mM 
Adjust pH to 7.9 
Elute buffer, 4X 
NaCl 2M 
Tris base SOmM 
Imidazole 2M 
Adjust pH to 7.9 
Strip buffer, 4X 
NaCl 2M 
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Chapter 3 Results 
3,1 Recombinant expression and characterization of neurosin 
3,1.1 Construction of neurosin prokaryotic expression vectors 
Human neurosin cDNA was cloned from the cDNA prepared from human 
SH-SY5Y cell line. To make SH-SY5Y cDNA, the total RNA was prepared by the 
Trizol reagent (Invitrogen) and the purified RNA was used as template to synthesize 
the first strand DNA by reverse transcriptase. The first strand cDNA was then used as 
template for amplification of neurons cDNA using primer pairs (XM5658-219F and 
XM5658-964R). The PCR product was analyzed by 1% agarose gel electrophoresis 
and the band of expected size (-750 bp) was successfully amplified (Fig 3-1). The 
PCR band was gel-purified and cloned into vector pCR2.1-T0P0, designated as 
neurosin-pCR2.1-TOPO. The identity of the clone harboring the neurosin cDNAwas 
confirmed by DNA sequencing (see Appendix C). The plasmid neurosin/pCR4 was 
used as template for second round PCR with primers with appropriate restriction 
sites (Bgl I I / Kpn I) flanked in pro-domain and catalytic domain of neurosin. 
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Fig 3-1 PCR amplification of neurosin cDNA 
Human neurosin cDNA (Genbank accession number D78203) was amplified by 
RT-PCR using total RNA of SH-SY5Y cells as template. PCR condition was: 94。C 
0:30，60。C 0:30, 70。C 0:45 for 35 cycles. The amplified PCR product of 〜750 bp 
was resolved in 1% agarose gel. 
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3.1.2 Prokaryotic expression of neurosin 
For small-scale protein expression, three clones of transformed cells are picked 
and inoculated in 2 ml LB medium. When the cells grew to mid-log phase (ODeoo = 
0.6), IPTG (1 mM) was added to induce protein expression. The cells without IPTG 
induction were used as control. When compared with the uninduced cultures, the 
induced cultures expressed an inducible 30-kDa protein, the size of which is 
consistent with the expected size of neurosin (Fig 3-2). 
In order to optimize the expression condition, the IPTG concentration and the 
time of induction were varied. The concentration of IPTG at 1 mM appears optimal 
as this concentration was routinely used among scientists working on protein 
expression. On the other hand, the duration of induction should be optimized since 
the target protein may be degraded when expressed for a long time. As shown in Fig 
3-3, protein expression level reached a plateau at 3 hours, indicating that three hours 
is the optimal duration for induction. Based on this preliminary characterization, 1 
mM EPTG and 3 hour-induction were routinely used for large-scale purification of 
neurosin. 
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Fig 3-2 Expression of neurosin in TUNER(DE3)pLysS 
Neurosin/pRSETA was transformed in TlJNER(DE3)pLyS. Protein expression was 
induced by addition of IPTG to a final concentration of 1 mM. The cells were 
harvested after 3 hours of induction and lysed by boiling in 1% SDS for 5 minutes. 
Three clones were selected for analysis by 12% SDS-PAGE. A significant protein 
band of 〜30 kDa appears only in the IPTG-induced cultures. The size of this induced 
protein is consistent with the expected size of neurosin. 
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Fig 3-3 Time course of neurosn expression 
The TUNER cells were induced by 1 mM IPTG and the cells were harvested at 1-hr 
intervals to 4 hours. Protein expression appeared to reach the plateau at 3 hours of 
induction. Protein samples were analyzed by a 12% SDS-PAGE. 
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3.1.3 Neurosin was expressed as inclusion bodies 
Recombinant protein expressed in E.coli exists as soluble cellular protein or in 
the form of inclusion bodies. The biologically active product should be present in 
soluble fraction while partially folded intermediate is present in the insoluble fraction. 
As shown in Fig 3-4, neurosin was expressed predominantly in insoluble fraction, 
presumably as inclusion bodies, a finding that has previously been reported (Babe et 
al. 2000). (Fig 3-4). Several measures were done to improve soluble protein 
expression. These measures included: to lower the expression temperature to 20°C, to 
reduce expression time interval and EPTG concentration, or to change E.coli strain to 
C41(DE3), Origami(DE3) and Rosetta-gami B(DE3)pLysS. (C41 is optimized for 
toxic protein expression, Origami is optimized for disulphide bond-rich protein 
expression, Rosetta-gami B has the feature of Origami and optimizes for rare codon 
protein expression.). However, none of these parameters improved the solubility of 
neurosin (data not shown). 
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Fig 3-4 Neurosin was expressed predominantly as inclusion bodies 
To fractionate the induced samples in soluble and insoluble fractions, harvested cells 
were resuspended in IMAC binding buffer and then lysed by sonication. The 
insoluble fractions pelleted by centrifugation at 30,000 x g for 30 minutes at 4°C. 
Both soluble and insoluble fractions were resolved in 12% SDS-PAGE. 
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3.1.4 Co-expression of molecular chaperones with neurosin 
In order to improve the soluble protein expression, a new approach that involves 
the co-expression of molecular chaperones together with the target gene was tried out 
in this study. It was previously suggested that molecular chaperones facilitate the 
folding of recombinant protein, thereby increasing the chance of producing soluble 
recombinant protein. The chaperone plasmids used in this study consisted of two 
families of heat-shock proteins DnaK-DnaJ-GrpE and GroES-GroEL. An artificial 
operon encoding DnaK-DnaJ-GrpE was constructed by inserting GrpE coding 
sequence into DnaK-DnaJ operon. DnaK-DnaJ-GrpE was placed under control of 
araB promoter of a pACYC184 based plasmid (Nishihara et al. 1998). GroES-GroEL 
operon was placed under control of Pzt-1 promoter and tet repressor. Therefore, 
overexpression of GroES-GroEL could be induced by tetracycline and 
DnaK-DnaJ-GrpE overexpression could be induced by arabinose (Nishihara et al. 
1998). A schematic diagram showing the mechanism of chaperone in assisting 
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Fig 3-5 Roles of the molecular chaperones in protein folding 
The newly synthesized polypeptide was protected by DnaK (K) and DnaJ (J) 
chaperones. GrpE accelerates the dissociation of DnaKJ and polypeptide upon ATP 
hydrolysis. About 10-15% of newly synthesized proteins require GroES and GroEL 
chaperones for folding. Other hsp family proteins may facilitate the folding but the 
mechanism is poorly understood. 
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In this experiment, the neurosin/pRSETA cDNA was co-transformed with 
plasmids encoding these chaperones. As mentioned above, both families of heat 
shock proteins are compatible and can be overexpressed separately or together. 
However, overexpression of heat shock proteins inevitability decreased the 
expression level of target protein. In order to overcome this problem, GroES-GroEL 
chaperones and neurosin were co-transformed first to see whether hsp60 proteins are 
able to assist refolding of neurosin. As shown in Fig 3-6, the molecular chaperone 
GroEL (MW ~ 57 kDa) was expressed primarily in soluble fraction. There was very 
little amount of neurosin (30 kDa) expressed in soluble fraction and almost all of the 
neurosin formed aggregates in insoluble fraction. 
In view of the small amount of soluble neurosin expressed using the GroEL 
chaperone system, another family of hsp - DnaKJ chaperone was tried. In this 
experiment, the effect of DnaKJ and GroESL on neurosin refolding was compared, 
as well as their synergistic effect on neurosin refolding (Fig 3-7). The members of 
hsp70 families expressed as three protein bands of DnaK (69 kDa), DnaJ (41 kDa) 
and GrpE (21 kDa) were shown. Most importantly, there was small but significant 
amount of neurosin present in the soluble fraction, compared to chaperone 
un-induced control (lane 1) and induced total lysate (lane 5). The co-expression of 
GroESL and neurosin appear not sufficient to facililate re-folding of soluble neurosin. 
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The expression of GroEL (57 kDa) assists neurosin refolding mildly, GroESL has 
less prominent effect than DnaKJ but still better than the cultures without any 
chaperone co-expression (lane 1). However, co-expression of DnaKJ, GroESL and 
neurosin (lane 4) did not seem to have any synergistic effect in producing soluble 
neurosin as the proteins expressed were similar to the one coexpression of DnaKJ 
alone (Lane 2). It is not surprising because at least 50% of proteins bind one or more 
hsp70 molecular chaperones during synthesis. Only 10% oiKcoli proteins and 15% 
of eukaryotic proteins bind to hsp60 molecular chaperones for refolding (Radford, 
2000). In addition, GroEL appears inefficient in helping the refolding of proteins 
greater than 60 kDa (Weissman et al. 1995; Mayhew et al. 1996). On the other hand, 
DnaK and DnaJ tend to bind small hydrophobic residues that are prone to aggregate 
during synthesis. DnaKJ may stabilize peptide by directly binding to them, protecting 
them from protease cleavage or adopting protease-resistant conformation. As 
neurosin is a hydrophobic and cysteine-rich protein, the assistance of DnaKJ 
significantly improves the solubility of neurosin. 
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Fig 3-6 Co-expression of GroESL and neurosin in E. Coli strain Origami (DE3) 
Origami (DE3) is a thioredoxin and glutathione reductase double mutant that 
facilitates disulphide bond formation of expressed protein in cytoplasm. GroES and 
G T O E L are members of hsp60 family. Molecular chaperone GroES and GroEL 
facilitates refolding of aggregated peptides. Origami co-transformed with 
pACYC184 based molecular chaperone expression plasmid pG-KJE8 (Nishihara et 
al. 1998) and neurosin/pRSET A. Cultures were induced with 1 mM IPTG (neurosin) 
and/or 0.5ng/ml tetracycline (GroESL) for 3 hours and then harvested for cell 
fractionation. The protein samples were resolved in a 12% SDS-PAGE. Lane 1， 
un-induced culture; lane 2, induced with I m M IPTG and 0.5 ng/ml tetracycline; lane 
3，insoluble fraction from induced culture; lane 4，soluble fraction from induced 
culture. 
71 
z z / 
/ / / 产 A 
KDa , / •^夕 
1 9 0 — 
1 2 0 - ^ j j j j j j jp S S B g ^ S J S L 
8 5 - H -DnaK ^B^^^K^H 一 GroEL 
： 丨 ： 置 m i -
• 爾 漏 爾 I 
1 - I 
w m m p . . 
Fig 3-7 Effect of molecular chaperone on soluble neurosin expression 
DnaK-DnaJ-GrpE are the members of hsp70 family while GroES-GroEL are the 
members of hsp60 family. DnaKJ assists protein refolding of newly synthesized 
peptides while GroESL facilitates refolding in later stage. The soluble fractions of 
cultures co-transformed with chaperones and neuronsin that were induced in different 
conditions were collected for SDS-PAGE analysis. Lane 1，soluble fraction induced 
with I m M IPTG (neurosin); lane 2, soluble fraction induced with ImM IPTG and 
Img/ml L-arabinose (DnaKJ); lane 3, soluble fraction induced with I m M IPTG and 
0.5 ng/ml tetracycline (GroESL); lane 4，soluble fraction induced with ImM IPTQ 
Img/ml L-arabinose and 0.5ng/ml tetracycline. 
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3.1.5 Purification of recombinant neurosin by immobilized metal affinity 
chromatography (IMAC) 
Recombinant protein fused with hexahistidine (6xHis) tag at either C-terminal 
or N-terminal can be purified by immobilized metal affinity chromatography (IMAC). 
Several divalent transition metal ions such as Co^^ Cu^^ and Ni^ "^  can bind to 
nitrilotriacetic acid (NTA) of the matrix. NTA forms four coordination bonds with 
I 
Ni hence immobilizes the metal ion, leaving two sites free to interact. The lone pair 
of nitrogen atom on histidine residue of protein forms coordinate bond with Ni^ "^ . 
However, only consecutive stretch of histidine residues binds tightly under stringent 
washing condition. Washing buffer contains low concentration of imidazole (60mM) 
and 0.2M NaCl. Sodium chloride is used to minimize non-specific binding and 
imidazole, the functional group of histidine, competes with single histidine mediated 
non-specific binding. Imidazole wil l bind all the sites of Ni-NTA resin except 
hexahistidine tagged recombinant protein. The 6xHis tagged protein wil l be eluted at 
higher concentration of imidazole (or lowering pH - protonated His residue or by 
chelating agent EDTA). 
In this experiment, the soluble fraction of the induced cultures was subjected to 
IMAC purification. During the washing steps, a lot of non-specific proteins were 
eluted at the first and second fractions. However, two bands are still visible in the 
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remaining wash fractions. DnaK and DnaJ overexpressed at least 10 fold more than 
endogenous chaperones and they still bound to the resin non-specifically. The 
recombinant neurosin was eluted at higher concentration of imidazole, along with 
molecular chaperones DnaK and DnaJ (Fig 3-8). The size of the eluted recombinant 
protein is of expected size of the target protein. The protein concentration of first two 
eluted fractions as measured by spectrophotometry and found to be 5.20 mg/ml and 
4.55 mg/ml respectively. In another set of experiment (Fig 3-9)，a slightly different 
washing procedure was carried out in which 10 volumes of washing buffer was used 
to wash to column in order to remove non-specific proteins bound to the resin more 
thoroughly. In this experiment, neurosin was mainly eluted at the first two fractions. 
The protein concentration of second fraction was found to be 3.64 mg/ml. However, 
recombinant neurosin only accounts for 1/3 (33-35%) of the purified product, as 
estimated from the intensity of SDS-PAGE gel photograph. The acual amount should 
be 1.77 mg/ml, 1.55 mg/ml (Fig 3-8) and 1.27 mg/ml respectively (Fig 3-9). When 
compared to the band intensity (neurosin) of cell lysate eluted fraction, the yield is 
estimated to be 6.35 mg/L (or 1,27 mg / 200 ml culture). 
It is obvious that the proteins at high molecular weights are corresponding to 
DnaK (69 kDa) and DnaJ (41 kDa) and the smaller one corresponded to neurosin (30 
kDa). The co-elution of chaperones could be explained by that fact that neurosin may 
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bind strongly with DnaK and DnaJ. 
The recombinant soluble neurosin being purified was further confirmed by 
immunoblotting probed with monoclonal anti-neurosin antibodies (Fig 3-10). A 
single band at 30 kDa in eluted fractions was strongly immunoreactive with 
anti-neurosin antibodies. 
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Fig 3-8 Purification of soluble neurosin by immobilized metal affinity 
chromatography ( IMAC) 
E. coli strain Origami (DE3) transformed with neurosin and chaperone vectors were 
treated with IPTG and L-arabinose, the soluble fraction was loaded to the affinity 
column and washed in 60 mM imidazole in 1-ml fraction. Neurosin (-30 KDa) was 
finally eluted after addition of 500mM imidazole in the eluting buffer. Residual 
chaperone DnaK, DnaJ and GroEL appeared to be co-eluted with the recombinant 
neurosin. 
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Fig 3-9 Purification of soluble neurosin by immobilized metal affinity 
chromatogaphy 
This experiment was the same as in Fig 3-8 except the washing steps were more 
extensive. Non-specific protein eluted after addition of 60 mM imidazole and 
neurosin was eluted after addition of 500mM imidazole. The bound impurities 
should be DnaK (69 kDa) and DnaJ (41 kDa) as they expressed in huge amounts that 
account for non-specific binding. Both wash and eluted fractions were analysed by 
SDS-PAGE. 
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Fig 3-10 Immunoblot of the purified soluble neurosin eluted from fraction o f lMAC 
The samples from each eluted fraction from IMAC were separated by 10% 
SDS-PAGE, electroblotted to PDVF membrane and probe with a monoclonal 
antibody against human neurosin (Abeam, 1:2000). A strong immunoreactive band 
was eluted in the first and second fraction during the elution steps. The size of the 
immunoreactive protein is consistent with the expected size of recombinant neurosin. 
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3.1.6 Enzyme assay 
In order to demonstrate the purified recombinant neurosin was functional active, 
an enzyme assay was set up to test the substrate and enzyme activity of the purified 
enzyme. The pro-sequence of neurosin may be cleaved through the autolysis by its 
own activity (Gomis-Ruth et al. 2002). Mouse and rat homolog of neurosin cannot 
autoactivate, thus neurosin and neurosin-like protease may be activated by 
lysine-specific protease (Matsui et al. 2000). 
In this experiment, trypsin activity was included as positive control because 
both neurosin and trypsin are serine proteases and share similar substrate specificites 
(Bemett et al. 2002). The fluorogenic substrate FVR-AMC was used in this 
experiment. FVR is the preferred substrate for thrombin, yet another serine protease 
similar to kallikrein. Arginine is the preferred PI and hydrophobic residues are 
preferred in P2 and P3, according to the crystal structure of binding pocket of both 
neurosin and thrombin (Bernett et al. 2002; Gomis-Ruth et al. 2002). On the other 
hand, trypsin does not have such preference, cleaving at arginine and lysine residue 
equally well. Another substrate, EKK-AMC, was also tested, to see whether neurosin 
can cleave effectively at lysine residue. 
As shown in Fig 3-11, both trypsin and neurosin could cleave FVR-AMC 
although neurosin cleaved less efficiently than trypsin. Trypsin cleaved EKK-AMC 
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effectively but neurosin failed to hydrolze efficiently this lysine specific substrate. 
This data suggest that neurosin is an arginine-specific protease. 
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The enzyme activity of trypsin and neurosin using fluoroqenic substrate 
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Fig 3-11 Enzyme activity of trypsin and neurosin using AMC substrates 
5[Lg trypsin and neurosin dissolved in assay buffer (50 mM TrisCl pH8 / 0.2% BSA), 
together with substrate FVR-AMC (S^g) or EKK-AMC (5^g). The mixture (100 ^il) 
incubated for overnight at 37°C and measured using a fluorescence plate reader (355 
nm for excitation and 460 nm for emission). Data are means± s.e.m.，n=3. 
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3.2 Effect of neurosin on APP processing in neuronal cells 
3.2.1 Generation of APP constructs 
Since APP is highly expressed in hippocampus, the APP cDNA was cloned 
using the human brain hippocampus cDNA (Clontech, USA) as template. To amplify 
APP cDNA, two pairs of nested primers (NM484-91F, NM484-138F, NM484-2463R, 
NM484-2524R) were used for nested PGR. After the second PGR, the APP cDNA 
was amplified as resolved by 1% agarose gel electrophoresis. APCR band of 〜2.1 kb 
was amplified (Fig 3-12). 
In order to investigate the cellular biology the C-terminal domains of APP, the 
full-length APP as well as the various APP-C-terminal fragments were cloned and 
fused upstream to the cDNA of a fluorescent tag EGFP. To facilitate efficient 
expression in mammalian cells, nucleotide sequences encoding a Kozak sequence 
with ATG codon were included in the forward primers (C##_HIND3). Two 
nucleotides were included in the reverse primer (APP GC SAL 1R) to allow 
in-frame transcription of fusion gene sequence of pEGFP-Nl. To amplify C-terminal 
fragments by PGR, APP695/pCR4-TOPO was used as template. The amplified DNA 
fragments were resolved by 1% agarose gel (Fig 3-13). A DNA fragment of expected 
size (~2.1 kilobases) was amplified. 
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Fig 3-12 Cloning of human amyloid precursor protein (APP695) cDNA 
The human APP695 cDNA (NCBI accession number NM_000484) was cloned by 
nested PCR using human hippocampus library cDNA (Clontech) as template. PCR 
condition was follow: For the first round PCR: 94°C 0:30，55。C 0:30, 68°C 2:20 for 
20 cycles. For the second round: 94°C 0:30, 60°C 0:30, 70。C 2:20 for 20 cycles. 
Primers for the amplification were shown in the Appendix. A DNA band 〜2.1 kb in 
size was successfully amplified as shown in this ethidium bromide stained agarose 
gel after electrophoresis. 
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Fig 3-13 PGR amplification of cDNA encoding various APP C-terminal fragments 
Various cDNAs encoding the C-terminal APP doamains APP-C99, APP-C83, 
APP-C59, APP-C57, APP-C50 and APP-C31 were amplified by PGR using 
APP695/pCR4-TOPO as template. The primers used were shown in the Appendix. 
The PGR conditions were: 95。C 1:00’ 55。C 0:30，68°C 1:00 for 40 cycles. PGR 
samples were separated on 1% agarose gel electrophoresis and visualized after 
ethidium bromide staining. 
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3.2.2 Expression of APP in mammalian cultures 
Several cell lines were evaluated for APP expression, which includes SH-SY5Y, 
HEK293 and COS-7 cells. These cells were first transfected with 
APP696/pCMV-tag 1, which contained N-terminal FLAG and C-terminal myc tags as 
FLAG-APP-myc fusion protein. It was originally thought that APP processing could 
easily be monitored by FLAG and c-myc immunoblotting. However, preliminary 
experiment showed that none of these cell lines demonstrated detectable APP 
expressed as detected by anti-FLAG and anti-myc antibodies by immunoblots. One 
possible explanation for the failure of these antibodies to detect APP peptides is that 
the N-terminal FLAG-tag may have been removed by signal protease. Another 
possibility is that the endogenous APP produced by these cell lines might 
compromise the exogenous APP expression. 
To overcome the problem that endogenous APP might have affected the 
heterologous expression of APP, a rat clonal neuroblastoma cell line B103 was 
studied for APP expression. B103 cells were a generous gift from Dr. Schubert of 
Salk Institute at San Diego, USA. These cells were demonstrated not to produce any 
detectable amount of APP (Schubert and Behl, 1993), thus providing a clean 
background for transfected APP expression. APP vectors APP695/EGFP, 
APP695-HA/pCMV-tagl and APP695/pcDNA3 were transfected to B103 cells and 
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the transfected cells were analyzed for the expression of APP by immunoblotting 
probing with a monoclonal anti-APP (6E10). As shown in the result of a typical 
immunoblotting analysis (Fig 3-14), two immunoreactive protein bands (one -120 
kDa and the other 〜160 kDa) were observed in the blot in cells transfected with 
APP695/EGFP and APP695-HA/pCMV-tagl, but not in the control (Fig 3-14 upper 
panel). Similarly, cells transfected with APP695/pcDNA3 (APPwt/pcDNA3) or 
Swedish mutant APP695 (APPsw/pcDNA3) were also shown to express a strong 
6E10 immunoreactive protein band at -100 KDa which were absent in the control 
cultures (Fig 3-14 lower panel). These studies indicate that transfected APP is 
efficiently expressed in B103 cells that are suitable for the analysis of APP 
processing. 
Two mutants APP were also generated, APPsw and APP(ISYEV). The APPsw is 
the well-known Swedish mutation that causes familial AD by increasing substrate 
specificity ( K M t D A — NL fDA) towards P-secretase. APP(ISYEV) is a synthetic 
mutant by substituting V K M | D A to ISYfEV. The substrate specificity for 
p-secretase is seven times higher than that of Swedish mutants. The expression of 
APP mutants was also further characterized. As shown in Figure 3-15, two APP 
mutants that were implicated to play a role in the genetics of familial Alzheimer's 
disease were transfected to the B103 cells, the 6E10 immunoreactivity in cell lysates 
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after transfected was compared. As demonstrated in the representative immunoblot, 
the cells transfected with wild-type or mutant APPs (APPsw/pcDNA3 and 
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Fig 3-14 Expression of human APP in B103 cells 
Representative immunoblots showing the expression of APP transfected with APP 
mammalian vectors in B103 cells. Cells were tranfected with 1 |j,g plasmid DNA 
with 2.5 |il Lipofectamine2000. After recovery for 48 hours, the cells were harvested 
and the total lysate were prepared. An amount of 20 |ig cell lysate was separated on 
7.5% SDS-PAGE, transferred to PVDF membrane and then probed with a 
monoclonal anti-APP (6E10) (1:5000，Signet Lab) antibody. Upper panel: cells 
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Fig 3-15 Expression of human APP and mutants in B103 cells 
B103 cells were transfected with various APP vectors as described in the Materials ! 
！ 
I 
and Methods. The total lysates (40 |ig) were run on 10% SDS-PAGE, transferred to 
PVDF membrane and then for probed with monoclonal anti-APP (6E10) (1:5000, 
Signet Lab) antibody. The APPsw and APPISYEV mutants were previously shown to 
increase the chance to develop familial AD in people having such APP mutations. 
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Previous study from other groups found that a compound 
N-[N-(3,5-dichlorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT) was 
able to inhibit Ap production mediated by y-secretase inhibition (Dovey et al. 2001). 
DAPT is a very specific y-secretase inhibitor with an IC50 to block Ap production at 
115 nM (Dovey et al. 2001). Treating DAPT on mouse neuronal cultures showed a 
remarkable (30%) decrease in sAPPp level but not sAPPa level. A plausible 
explanation is that both P-secretase and y-secretase were inhibited by DAPT. 
In order to understand more about the pathway of APP processing, the cells 
transfected with APP vectors were treated with this specific y-secretase inhibitor 
DAPT. APP-transfected B103 cells were treated with 250 nM DAPT for 24 hours. 
The cells were then harvested and the total cell lysates were prepared, resolved by 
15% SDS-PAGE, transferred to PVDF membrane and finally probed with anti-APP 
(C-terminal 22 residues) and 6E10 (Ap 1-16) antibodies. Full length APP expressed 
in B103 cells and C-terminal fragments accumulated in DAPT-treated cells (Fig 
3-16). 
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Fig 3-16 Effect of DAPT on APP processing in B103 cells 
B103 cells were transfected with APP vectors for transient expression of APP. It was 
followed by an overnight incubation with or without y-secretase inhibitor DAPT (250 
nM). The total lysates from each culture (20 |ig) were run on 15% SDS-PAGE, 
transferred to PVDF membrane and then probed with 6E10 or anti-CT695 
(recognizes the APP C-terminal epitopes). Upper panel: The membrane strip probed 
with and-APP 6E10 (1:5000，Signet Lab). Lower panel: The membrane strip probed 
with anti-CT695 (1:5000, Sigma) showing the accumulation of the C-terminal 
fragment of APP in DAPT-treated cells. DAPT is a y-secretase inhibitor that prevents 
further processing of C-terminal fragments 
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3.2.3 Cellular localization of APP and its processing products 
The objective of this series of experiments is to investigate the cellular 
expression of APP and its C-terminal domains in neuronal cells. The cDNAs 
encoding the full-length APP695 or the C-terminal regions of APP were fused 
upstream to a gene encoding green fluorescent protein (EGFP). Various C-terminal 
fragments were identified in the brains of AD patients (Passer et al. 2000) that would 
appear to participate in signaling events between plasma membrane and nucleus 
(Kimberly et al. 2001). The C-terminal APP fragments were known to activate 
transcription by binding with Fe65-Tip60 or Fe65-CP2/LSF/LBPl complex. In 
addition, these C-terminal fragments represent the processing product of secretases 
or caspase as shown in Fig 3-17. These fusion constructs were then transfected to 
PC 12 cells for transient expression of APP-GFP fusion proteins. The cells were 
grown on coverslips and then mounted onto a perfusion chamber for fluorescence 
microscopy examination. The fluorescence in the cells was captured and visualized 
by laser confocal microscopy. 
As shown in Fig 3-18，APP/EGFP is mainly distributed in endoplasmic 
reticulum, Golgi apparatus and cell surface. In addition, green fluorescence was also 
observed at the terminals of neurites, a finding consistent with the transportation and 
expression of APP at the synapses. 
93 
In cells transiently expressed with APP-C99/EGFP and APP-C83/EGFP, the 
green fluorescence was mainly focalized in the peri-nuclear space, a pattern similar 
to the localization of APP/EGFP (Fig 3-19). No fluorescence was observed in the 
nucleus. Unlike C99 and C83, APP-C59/EGP is mainly localized in the nucleus, 
which agrees the role of C59 as APP intracellular domain (AICD) (Fig 3-19). C59 
has a PTB binding motif (YENPTY) that recognizes Fe65-Tip60 or 
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Fig 3-17 The generation of constructs containing the APP695 C-terminal fragments 
fused with EGFP 
A schematic diagram showing the various constructs used in confocal microscopy 
experiment. C99 is generated by p-secretase cleavage of APP, C83 is generated by 
a-secretase cleavage and C59 is generated by y-secretase cleavage. The C31 is 
proposed to be generated by caspase-3. 
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Fig 3-18 Cellular localization of APP-EGFP 
The cDNA encoding the full-length APP695 was fused with the gene coding for to 
generate the fusion construct APP-EGFP. This vector was transfected to NGF 
differentiated PC 12 (PCI2D) cells and examined with laser confocal miscroscopy 
(Leica). The fluorescence of APP-EGFP was mainly localized in endoplasmic 
reticulum, Gogli apparatus, but not in the nucleus. There was also evidence that APP 
was transported to the nerve terminals (as indicated by an arrow on the figure). As 
control, the cells transfected with EGFP vector expressed GFP evenly in the cells 
(top right comer). Scale bar = 8|im. (n=10) 
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Fig 3-19 Cellular localization of APP C99-EGFP, C83-EGFP, C59-EGFP and 
C50-EGFP (left to right) 
C99, C83 and C50 fused with C-terminal tagged EGFP were transfected to PCI2D 
cells. The distribution of C99 or C83 is similar to APP. This is because both C99 and 
C83 retained transmembrane domain of APP. Both C99 and C83 localized in 
perinuclear space. None of them translocated to the nucleus. For C50-GFP, it 
expressed as cytosolic protein since it does not retain transmembrane domain, 
cleaving near ER retention signal (KKK) of type I integral protein. C59 is the normal 
processing product by y-secretase after initial cleavage by a-secretase or (3-secretase. 
In C59-EGFP transfected PCI2D cells, C59 appears to localize in the nucleus. Scale 
bar = 8|im (n=3) 
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3.2.4 The role of over-expression of neurosin on APP processing in B103 cells 
Based on the previous results, it is concluded that the rat neurobloastoma cell 
B103 cell is a useful cell model for the subsequent analysis of the role of neurosin on 
APP processing. A previous study by Little et al. (1997) has provided the first 
evidence that this enzyme may play a role in APP processing but the details of the 
mechanisms is not fully characterized. In this study, it is proposed that neurosin may 
have differential effects on APP processing. 
When APP and neurosin were co-transfected in B103 cells, the expression level 
of cellular APP in cells overexpressed with neurosin was lower than that in APP 
transfected cells, as detected by immunoblotting with monoclonal anti-APP (6E10) 
(Fig 3-20). The antibody 6E10 recognizes the epitope of Api-16. One possibility to 
account for this observation is due to an increase in cellular processing of APP to 
release soluble APPs. However, the band intensity of APPwt/neurosin is lower than 
that of APPsw/neurosin and APP(ISYEV)/neurosin, we cannot rule out the 
possibility that neurosin cleaves APPwt more effectively than those mutants. Further 
experiment is needed to give a conclusive answer to this problem. It appeared that 
the levels of cellular A P P in cells transfected with A P P mutants (APPsw or A P P I S Y E V ) 
were not decreased as much as in the wide-type control, indicating that neurosin may 
be less efficient to process the APP mutant proteins in B103 cells (Fig 3-20). 
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Fig 3-20 Effect of over-expression of neurosin on APP expression in B103 cells 
B103 cells were transfected with either A P P vectors ( A P P , APPSW or APPISYEV ) or 
together with neurosin vector. After transfection, the total cellular protein lysates 
were prepared and approximately 55 }xg of each were separated on 10% SDS-PAGE, 
transferred to PVDF membrane for immunoblots probed with 6E10 (APP) 
(dilution 1:5000) or 2B2-6 (neurosin) (dilution1:2000). Anti-actin immunblot was 
carried out to normalize the amount of proteins loaded in each lane. Lane 1, APP 
wide-type (APPwt)； lane 2，APPwt + neurosin; lane 3，APP Swedish mutant (APPsw； 
lane 4，APPsw + neurosin; lane 5, A P P ISYEV mutant (APPISYEV)； lane 6; APP(ISYEV) 
+ neurosin. 
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Chapter 4 Discussion 
4.1 Discussion of neurosin expression 
Neurosin (or human kallikrein 6/zyme/protease M) is a brain-specific 
trypsin-like protease belongs to the kallikrein family (Yamashiro et al. 1997; Yousef 
et al. 1999; Ogawa et al. 2000; Okui et al. 2001; Iwata et al. 2003). Among them, 
neurosin is a putative target for drug development as it has been proposed as a 
biomarker of certain breast and ovarian cancers and Alzheimer's disease (Yousef et 
al. 2003). Therefore, it is of great interest to functional express this enzyme for 
biochemical characterization. Previously studies have shown that neurosin could be 
successfully expressed in Pichia pastoris (Gomis-Ruth et al. 2002)，HEK293 cells 
(Diamandis et al. 2000), CHO cells (Ogawa et al. 2000) and baculovims/insect cell 
line system (Bemett et al. 2002). Neurosin could also be expressed in soluble form in 
a gram-positive bacteria Rhodoccoccus erythropolis (Nakashima et al. 2003), albeit 
in small quantity (0.3-2 mg/L). However, none of the studies are successful for 
functional expression in E. coli. In view of the fact that the prokaryotic expression 
system is still the cheapest and quickest way to produce recombinant protein, the 
objective of the present study is to evaluate several strategies for the prokaryotic 
expression of neurons under different conditions. One of the strategies used in this 
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study is to apply the co-expression of molecular chaperones with the target plasmid 
so as to increase the cellular solubility of the recombinant proteins (Nishihara et al. 
1998). This system makes use of heat shock proteins DnaK-DnaJ-GrpE (hsp70) and 
GroEL-GroES (hsp60) to facilitate the refolding of recombinant proteins. 
The objective in the present study is to express recombinant neurosin using the 
prokaryotic expression system. In this experiment, T7 expression system is used. 
DE3 X phage lysogen carried T7 RNA polymerase transfected to the E.coli and T7 
RNA polymerase gene integrated to the genome (Studier and Moffatt, 1986). The 
advantage using T7 RNA polymerase is that this polymerase binds to T7 promoter 
specifically to initiate transcription, and the activity of T7 RNA polymerase is five 
times higher than that oiE.coli (Chamberlin and Ring, 1973). However, one major 
disadvantage is that T7 RNA polymerase directed by efficient upstream signals of 
gene 10，which is a major capsid protein of T7 phage, the first eleven codons should 
be included in recombinant protein (Schoepfer, 1993). However, the expression level 
can be controlled by IPTQ as IPTG initiates the transcription of T7 RNA polymerase 
under the control of lacUVS promoter (Studier and Moffartt, 1986). 
Initial experiment involved the transformation of neurosin/pRSET A to 
BL21(DE3)pLysS for expression (Schoepfer, 1993). BL21 belongs to B strain rather 
than commonly use K12 strain. B strain lacks Ion and ompT protease that degrades 
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newly synthesized recombinant protein (Grodberg and Dunn, 1988). The co-plasmid 
pLysS is a pACYC184-based plasmid that code for T7 lysozyme. T7 lysozyme is a 
bifunctional protein. It can cleave peptidoglycan layer of E.coli cell wall. The 
expression of lysozyme is unlikely to access to the outer cell wall therefore it wil l not 
degrade the cell wall itself. Alternatively, it can bind T7 RNA polymerase, inhibiting 
the initiation of transcription (Inouye et al. 1973; Moffatt and Studier, 1987). The 
fractionation of proteins revealed that recombinant neurosin was present in insoluble 
fraction (inclusion bodies) (Fig 3-4). Neurosin is a trypsin-like protease that share 
many common features. Similar to the structure of trypsin, neurosin has six 
disulphide bonds in its two p barrel conformation. Numerous disulphide bond 
formation is particular problematic in prokaryotic expression because the redox 
potential in the cytoplasm (-270 mV) is low in E.coli (Mossner et al. 1999). 
Disulphide bonds wi l l not form in the cytoplasm of E.coli even cysteine residues 
made up of 30% of the whole protein. The reducing cytoplasm is maintained by 
thioredoxin reductase {trxB) and glutathione reductase {gov). Therefore, the condition 
can be reversed by trxB and gor inactivation, making the cytoplasm in a more 
oxidized state that is similar to mammalian cytoplasm in term of the redox potential 
(Bessette et al. 1999). On the contrary, one can express target protein in periplasm 
which is more oxidizing than cytoplasm. A commercially available E.coli strain 
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called Origami(DE3) has trxB and gor double mutations. It was found that this strain 
is much more suitable for the expression of proteins with high degree of disulphide 
linkage. 
Molecular chaperones are a group of proteins that have functions to assist the 
folding of newly synthesized polypeptide or wrongly folded proteins (Fig 3-5). For 
example, 14 cysteine residues of SPARC (secreted protein acidic and rich in cysteine) 
cause the protein hard to fold correctly, as random disulphide bonds wil l form during 
oxidation. The protein has been successfully expressed in correct form by 
co-expression of DnaKJ operon in a trxB mutant enhances the solubility of SPARC 
(Schneider et al. 1997). Therefore, a similar approach was adopted here to increase 
the solubility of neurosin. The result presented here indicated that co-expression of 
GroESL chaperonins alone with neurosin only increases the solubility of neurosin 
slightly (Fig 3-6); indicating the folding of neurosin is not assisted by GroESL. In 
contrast, the solubility of neurosin increases significantly by coexpressing with 
DnaKJ chaperonins (Fig 3-7). This data suggest that co-expression of GroESL and 
DnaKJ are necessary to improve the functional expression of soluble form of 
neurosin. 
Molecular chaperones other than DnaKJ / GroESL may be tried in the future for 
any further improvement in protein expression. For example, a prolyl cis/trans 
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isomerase called trigger factor (Nishihara et al. 2000) may assist the folding of 
neurosin better because the crystal structure of neurosin reveals c/5-proline residues 
in critical region (Bemett et al. 2002). Other molecular chaperones, such as 
periplasmic disulphide isomerase DsbC (Chen et al. 1999) and periplasmic prolyl 
cis/trans isomerase Skp (Chen et al. 1996)，may also facilitate the folding of neurosin. 
Whether this is the case awaits further investigation. 
Even though the soluble recombinant neurosin has been successfully expressed 
in this improved expression system, the purification of highly purified neurosin is 
still a challenging task. There were substantial amount of protein impurities eluted 
along with recombinant neurosin during the affinity chromatography steps. It has 
been known that some E.coli proteins such as superoxide dismutase (SOD) (Pesce et 
al. 1997) or rotamase (SlyD) (Hottenrott et al. 1997)，have metal binding domains 
that might bind NP^ of Ni-NTA column. In addition, molecular chaperones DnaK 
and DnaJ co-purify with neurosin, accounting for the three protein bands consistently 
observed during the elution steps (Fig 3-9). Although the co-eluted DnaK and DnaJ 
may not interfere with the protease assay, there is still necessary to remove the 
chaperones probably by other means. To further purify recombinant neurosin, DnaK 
and DnaJ can be removed by size exclusion chromatography, for the size of 
molecular chaperones is higher than that of neurosin. In addition, neurosin is a 
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trypsin-like serine protease, which can be purified by affinity chromatography. Serine 
protease ligand resins such as aminobenzamidine, aprotinin or soybean trypsin 
inhibitor are suitable for this purpose. 
Neuorsin showed the expected enzyme activities as demonstrated by its 
cabability to hydrolyze the Arg- and Lys-specific fluorogenic substrates, which 
agreed the prediction from neurosin crystal structure. It is interesting to find that 
neurosin has a preference for Arg- rather than Lys- cleavage (Fig 3-11) and may have 
functional significance in vivo where this enzyme processes the endogenous 
proteins/peptide substrates In the future, this enzyme wi l l be tested for its ability to 
cleave the peptide substrates, particularly those peptides that are involved in the 
amyloidgenesis of APR In summary, the work presented here demonstrated that 
neurosin could be functional expressed in prokaryotic system assisted by 
co-expression of molecular chaperones. 
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4.2 Discussion of APP cell model 
One of the major goals of the present study is to establish a reliable cell model 
expressing APP and its mutants. The cell model has many advantages for cellular 
biological study of APP processing. For instance, the proteolytic processing of APP 
can be investigated in details by monitoring the processed peptides within the cells or 
in the culture media. The cell model is also amendable for drug intervention to study 
any drug effect on the modulation of specific proteolytic processing. In our 
experiment, B103 and PC 12 were used as cell model. 
B103 is a clonal cell line derived from rat CNS nerve. B103 cells have 
neuron-like property but retain the proliferation ability. The most unusual property of 
B103 cells is their lack of producing amyloid precursor protein, as demonstrated 
from Northern blot and Western blot analysis (Schubert et al. 1993). This property 
provides a great opportunity to investigate the processing of APP after transfection of 
native or mutant APPs to these cells. B103 cells showed a tendency towards the 
degradation of cell sheets when the growth reached the plateau. B103 cells can be 
differentiated into neuronal cells by treating with 1 mM dibutryl-cAMP (Ishii et al. 
1990). 
PC 12 (atcc# CRL-1721) is a transplantable rat pheochromocytoma cell line that 
produces various catecholamines, particularly dopamine. It is an adrenal carcinoma 
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that exhibits neuroendocrine properties. PC 12 cells can be reversible differentiated to 
dopaminergic neurons by treating with nerve growth factors (NGF) (Greene et al. 
1976). PC 12 cells produce endogenous APP and it is therefore a popular cell model 
to study the cell biology of APP processing. In the present study, the cellular 
localization of various GFP-tagged APPs was examined. 
There have previously been reports on the APP processing in different cell types. 
For example, APP has been found to be localized in the basolateral domain but not 
apical domain of MDCK cells (Haass et al. 1994, 1995; DeStrooper et al. 1995a, 
1995b), in the axonal region rather than somatodendritic region (Simons et al. 1995; 
Yamazaki et al. 1995). B103 cells are particular useful in developing APP mutants 
cell model to investigate any cellular changes resulting from the over-production of 
wild-type or mutant APPs. This study demonstrated that both wild type and mutant 
APPs (APPsw and A P P I S Y E V ) are efficiently expressed as high molecular weight A P P 
in B103 cells (Fig 3-15). PC12 cells were used for sub-cellular localization study as 
it was found that differentiated PC 12 cells retained many neuronal phenotypes that 
are suitable for microscopic examination. 
The expression pattern of EGFP-tagged APP fusion proteins in B103 cells is 
consistent with the findings previously obtained from other cell types (Simons et al. 
1995; Gao et al. 2001; Kinoshita et al. 2002). In the present study, it was found that 
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APP-EGFP is typically expressed as two major bands in Western blot analysis, 
presumably in different glycosylated forms (Hung et al. 1994; Walter et al. 1997) 
(Fig 3-14 upper panel). Similar results were also found in cells transfected with APP 
construct cloned in pcDNA3 that were immunoreactive to antibody 6E10 (Fig 3-14 
lower panel), a well-characterized monoclonal antibody for the detection of peptide 
containing the Ap-containing epitiopes. This monoclonal antibody 6E10 was made 
by immunization with Apl-17. APP and its mutants expressed in B103 cells are 
expressed as 〜100 kDa protein band, presumably representing the unprocessed form 
of glycosylated APR However, there are many non-specific bands in the blots probed 
with 6E10. Because anti-APP 6E10 antibodies recognized human Ap 1-16 but not 
mouse or rat (the epitope is slightly different), the antibody may cross-react with rat 
proteins. Both B103 and PC 12 cells are rat origin and may explain why we can get a 
clear blot using human cell line but not rat cell line. 
The use of potent y_secretase inhibitor DAPT further confirmed the 
6E10-immunoreactive proteins as APP. In cells treating with DAPT, there is retention 
of 〜10 kDa protein in the total cell extracts, indicating the accumulation of C99-like 
fragment in these cells in response to DAPT treatment (Fig 3-16). 
Another objective of the present study is to investigate the cellular localization 
of APP and its C-terminal domains. The cellular localization of APP-EGFP revealed 
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that APP is localized in the perinuclear regions and in the neurites, presumably in the 
Golgi apparatus and in the nerve terminals. This observation is in line with the role 
of APP as a transmembrane protein, which is actively transported to the nerve 
terminals (Fig 3-18). Similar cellular distribution of APP-C99-EGFP and 
APP-C83-EGFP in the cells were found, indicating that the APP-C-terminal domains 
that contain the Api_42 domain exist predominantly in membrane-tethered form (Fig 
3-19). 
The most interesting finding of this study is the observation that 
APP-C59/EGFP is expressed mainly in the nucleus, a property not shared by 
APP-C50/EGFP, which is localized in the cytosol. The APP-C59 domain is generated 
by the final step of APP cleavage at the 丫-site，presumably by the action of 
presenilin-dependent y-secretase (Fig 3-19). The observation that C59 is localized 
mainly in the nucleus is of particular interest regarding the recent suggestion that the 
C-terminal intracellular domain of APP might have important physiological role 
mediating gene transcription in the cell. A specific nuclear localization signal was 
found at the N-terminal region in C59, which is absent in C50 domain that is devoid 
of the nuclear localization signal (NLS) (Kopan et al. 2004). This observation is in 
favor of the proposition that the C-terminal intracellular tails of APP could be 
shuttled to the nucleus mediating many nuclear-specific cellular signaling events, and 
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the NLS of APP-C-terminals is an important motif for regulating APP-mediated 
cellular function. 
The APP intracellular domain (AICD) is generated by the y-secretase mediated 
cleavage of APP. AICD refers a group of C-terminal peptides resulting from 
processing of APP, that include the C99, C83, C59, C57, C50 and C31. Both the 
three secretases and caspases participate in APP processing to release the APP 
C-terminal peptides. The exact physiological function of AICD remains controversial. 
The central question is that whether AICD-mediated cellular signaling contributes to 
AD pathogenesis. C99 and C31 have been found to mediate cellular toxicity that 
might have implications for the neuronal cell death in AD (Bergman et al. 2003). 
In parallel to Notch intracellular domain (NICD), AICD is thought to mediate 
transcription in similar manner. AICD was found to bind to various interacting 
proteins to form a large complex (Fig 4-1). For instance, AICD binds to Fe65 adaptor 
protein, which in turns binds to Tip60 or CP2/LSF/LBP1. Notably, AICD-Fe65 
prefers to form complex with Tip60 (Cao and Sudhof, 2001), a histone acetylase but 
NICD prefers to bind to Fe65-CP2/LSF/LBPl (Zambrano et al. 1998). Thus AICD 
and NICD have important role to transactivate different promoters of specific target 
genes. In connection to these findings, it has recently been reported that AICD could 
up-regulate the GSK-3P gene transcription through tranactivation of its specific 
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promoter (Kim et al. 2003)，thus providing an interesting link between the 
biochemical process of amyloidogenesis and tauopathy observed in AD. 
The amyloidogenic potential of neurosin was first reported by Little et al. (1997) 
who identified the then unknown serine protease in AD brain which is highly 
homologous to trypsinogen I-IV. This protease was hence named neurosin. Neurosin 
also has catalytic triad motif (TAAHC, DIMLL, GDSGGPL) similar to other serine 
proteases (Little et al. 1997). Neurosin was also shown to be able to process APP in 
vitro (Little et al. 1997). The concentration of neurosin correlates with AD 
pathogenesis and ovarian/breast cancer formation (Diamandis et al. 2000). Neurosin 
is a secretable enzyme that is found in mitochondrial, microsomal but not cytosolic 
fraction (Iwata et al. 2003). UV and oxidative stresses were found to cause neurosin 
secretion (Iwata et al. 2003). Neurosin is mainly expressed in microglia, 
oligodendrocyte and epithelial cells of choroid plexus (Scarisbrick et al. 2001). This 
expression of neurosin suggests its participation in myelin turnover and 
inflammatory response (Scarisbrick et al. 2002). The main function of choroid plexus 
is to produce CSF and this may explain why the level of neurosin is so high in CSF 
of AD patient. Therefore, the release of neurosin from mitochondrial fraction might 
be the response to general insult mediated by the pathological production of AP and 
C-terminal fragments. A recent study suggested the putative degradative role of 
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neurosin on a-synuclein, a brain protein implicated in the pathogenesis of 
Parkinson's disease. In the degradation of a-synuclein, neursosin cleaves the lysine 
residue at the KTKEGV repeats (Iwata et al. 2003). Similar role of neurosin in 
processing APP is also proposed. Such cleaving events prevent polymerization of Ap 
and a-synuclein. 
The crystal structure of neurosin has recently been elucidated (Bemett et al. 
2002). In kallikrein family, the 11-amino acid residues inserted between the sixth and 
seventh P sheets, additional residues are known as kallikrein loop. The kallikrein 
loop is a characteristic of regulatory protease. However, this loop is missing in the 
case of neurosin. The length of this loop in neurosin is indistinguishable in 
comparison with the degradative protease trypsin (Bernett et al. 2002). A short 
surface loop oriented away from active site which is same as trypsin but not other 
members of kallikreins. The loop ranged from residue 141-152 is shorter than trypsin 
and oriented away from active site (Bernett et al. 2002). In general, degradative 
proteases have shorter loop in this region, while the regulatory proteases have longer 
loops to accommodate more extensive structural determinants of the 
substrate-binding site (Bemett et al. 2002). 
Neurosin is also known as a kallikrein-like protease that involves in 
demyelination (Scarisbrick et al. 2002) and a-synuclein degradation (Iwata et al. 
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2003). Based on the present result, it is suggested that neurosin might also play a 
definitive role in the degradation of amyloid peptides (Fig 3-20). There are many 
putative cleavage sites found in APP that could be hydrolyzed by neurosin. Notably, 
one within the Ap region and one site occurs in the APP-CTF region. Therefore, i f 
these sites were cleaved by neurosin, the anti-Ap and anti-APP-CTF antibodies may 
not to able to detect the degradative products of APR This may explain why the cells 
over-expressed with neurosin showed less amount of large MW APP because of the 
increase in APP degradation by neurosin. However, we cannot rule out the possibility 
that the difference in APP expression level is due to competition of transcription or 
translation resources. To clarify the result, we can construct a non-flinctional mutant 
construct of neurosin as control. Another observation is that neurosin seems to cleave 
APPwt more effectively than the mutants. One possible reason is that a lysine residue 
is retained in APPwt (VKMtDA) but not in those mutants (VNLtDA, ISYtEV). 
Neurosin may cleave this lysine residue at high concentration, just as neurosin 
cleaves lysine residues in a-synuclein, even though neurosin preferentially cleaves 
arginine residue. Further characterization by other methods, such as radioactive 
labeling/co-immunoprecipitation, is necessary to explore this possibility. In this study, 
the cellular level of APP was found to be significantly lower that the cultures 
over-expressed with neurosin. This data is consistent with the hypothesis that APP is 
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a substrate of neurosin. Unfortunately, an attempt to measure theA(3 formation in the 
culture media was unsuccessful due to the technical problems on the specificity of 
antibody in ELISA detection of secretable APP. Nevertheless, the present study 
confirmed that neurosin could degrade cellular APP. 
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Fig 4-1 A schematic diagram showing a working model for AICD mediated 
transactivation of target genes 
The APP intracellular domain (AICD) is proposed to mediate transcription through 
interacting with Fe65 and other protein complex. AICD, generated after y-secretase 
cleavage of APP, binds to Fe65 through the interactions on WW (di-trytophan 
residues domain) and PTB 1/2 domains. The activated Fe65 or Fe65/AICD complex 
is translocated to the nucleus and then form complex with Tip60 to mediate gene 
transcription (Adapted from Cao and Sudhof, 2004). 
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Fig 4-2 Putative neurosin cleavage site in APP 
This diagram annotated putative cleavage site o f APP by neurosin. Neurosin 
preferentially cleaves at arginine residues at P I and bulky residues at P3, The 
residues underlined represent Ap region. 
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4.3 Conclusion 
Despite the various difficulities in the intitial effort on the purification of 
recombinant neurosin in bacteria, the present study demonstrates that the 
co-expression of molecular chaperone in the bacteria improves the solubility and 
yield of recombinant neurosin. This method deserves to have a wider acceptance in 
the view of the fact more functional protein could be produced and purified 
compared to the conventional methods. There are obvious advantages of this system 
in comaprison to the previous attempts to produce recombinant neurosin such as in 
the mamalian cells and in the Drosophila insect cells. This method is fast and the 
production cost is substantially cheaper than the above-mentioned methods. The 
neurosin enzyme analysis confirmed that the recominant neurosin has a substrate 
prefereance towards agrinine clevage over the lysine residues. 
The present study also sucessfully established a reliable cell model to study the 
metabolism of APP processing. Due to the time constriaint, the details in APP 
processing of the mutant constructs have not been fully characterized. Future work is 
necessary to exploit this cell system. By studies the various GFP-flision constructs of 
C-terminal APP, it is intriguing to demonstrate that the C-terminal C59 appear to 
enter the nucleus, presumbly to trigger important nucleur funciton This result 
confirmed the significance of y-cleavage and its role in APP signalling. 
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Overexpression of neurosin in APP-transfected B103 cells appears to decrease 
the cellular level of APP. This could be attributed to the increase in the 
metabolism/degradtion of membrane-bound APP precursor. This observation is 
consistent with its proposed role as a major degradative enzyme of APP processing. 
However, due to technical difficulties, APP processed products in culture media were 
unable to detect, probably because of the failure of the monoclonal antibody to detect 
secretable APPs. Future attempt is needed to confirm whether overexpression of 
neurosin increase secretable APP products in the culture media. 
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Appendix A Tables on primers used in this study 
APP-related primers 
NM484-91F gga cgc ggc gga tcc cac tc 
NM484-138F cag ggt cgc gat get gcc c 
NM484-2463R ggt eta gtt ctg cat ctg ctc 
NM484-2524R gac acc gat ggg tag tga ag 
APP_K0ZAK_HIND3_F gca age ttg cca ccA TGc tgc ccg gtt tgg cac tg 
APP_GC一SallR aag teg acg cgt tct gca tct get caa a 
APP-STOP一Sail ttg teg acc tag ttc tgc ate 
C99一HIND3 gca age ttg cca ccA TGg atg cag aat tcc ga 
C83一HIND3 gca age ttg cca ccA TGt tgg tgt tct ttg ca 
C59一HIND3 gca age ttg cca ccA TGa tag cga cag tga tc 
C57一HIND3 gca age ttg cca ccA TGa cag tga teg tea tc 
C50_HIND3 gca age ttg cca ccA TGg tga tgc tga aga ag 
C31一HIND3 gca age ttg cca ccA TGg ccg ctg tea ccc ca 
KM670/671NL一F gag ate tct gaa gtg aac ctg gat gca gaa ttc eg 
KM670/671NL_R egg aat tct gca tcc agg ttc act tea gag ate tc 
APP_ISYEV_F ate age tac gaa gtc gaa ttc cga cat gac 
APP_ISYEV_R gac ttc gta get gat ttc aga gat ctc ctc 
KLK6-related primers 
XM5658-219F gcg gcc atg aag aag ctg atg g 
XM5658-964R cag ggt cac ttg gcc tga atg g 
KLK6_KQZAK_BGL2_F gaa aga tct gcc acc ATG aag aag ctg 
KLK6_XH01 att ctc gag tea ctt ggc ctg 
KLK6一XHOl一2 att ctc gag ctt ggc ctg 
KLK6M_BGL2 taa gat ctg agg age aga ata agt tg 
KLK6M_KPN1 ttg gta cct cac ttg gcc tga at 
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Appendix B Plasmid map 
Bg/n (610) 
iXhol (614) 
^ ^ Sad (621) 
如Rl(m) 广 咖丨（购 
/ I pEGFP-NI/APP \ , 
/ ^ 1 703^ bp | t 一 
f PC … A P P \ 
I 6282 bp I \ j y Ba^HHm2) 
\ >、、 Ecoia (2648) 
^ Z - R, 0325) , 
&oRI(262g) a ™ HI (2962) 
^ 3«:1(656) 
ff an (7688) 如II (13) 
f pCMV-Taol/APP 
II 6602 bp U 卿 / 、 一 ） 
\ JJ I pcDNA3iAPP 
X j/广 ai«H[(2280) I 7689 bp .1-—— 
划11(2720) \ am HI (2455) 
&oBI(2r746) J^ SaclQUi) 
、San (3037) \Sg in (2895) 
_, Afel(3043) ^"^(2921) 
W ( 3 0 8 2 ) 如 脚 〉 
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flirt dill (235) 
,Kpn\ (245) 
-S^d (251) 
Z 如 RI(284) 
ff N \ Neurosin 
/ \ \ &7«HI (1002) 
pCR2.1-TOPO/Neurosin f V .. 
4666 bp \ 
^ I Xho\ (1070) 
w 
Bglll (2019) 
/ / \ \ B7«HI(867) 
pRSETA/Neurosin I L 
** (900) 
3565 bp i T K 
\\ Jf (卯5) 
\ / ^ftndlll (912) 
f - g r 。 E 、 
I PG-KJE8 groEsQ 
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^^^^^ rrnBT1T2 
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Appendix C DNA sequencing 
APP/pCR4-TOPO sequencing (M13 rev primer) (NM484-1A-M13rev(-29).scf) 
>gi 113325111Igb IBC004369. 11 11 Homo sapiens amyloid beta (A4) preCurSor protein (protease 
nexin-II. Alzheimer disease) • .RNA (cDN! clone 
lUAOE: 3639S99). complete cds 
Length ... 1319 
Score = 741 bits (374). Expect = 0.0 
Identities = 374/374 (100~) 
Strand = Plus 1 Plus 
Query: 230 gattcaratccatca",accaaaacctgcattgataccaargaa,gcatcctgca,tat 289 
111111111111111111111111111111111111111111111111111111111111 
Sbjct : 283 gattcagatccatca"gaccaaaacctgcattgataccaargaaggcatcctgca,tat 342 
Query: 290 tgccaagaagtctaccctgaactgcagatcaccaatgtggtagaagccaaccaaccagtg 349 
1111 " I I I I I I I I I I I III I I I " " 11111 " I 11 III I 11 111111 11111111111 
Sbjct : 343 tgccaagaagtctaccctgaactgcagatcaccaatgtggtagaagccaaccaaccagtg 402 
Query: 350 accatccagaactggt,caa,c"ggccgcaagcagtgcaagacccatccccactttgt, 409 
I " " I I I I 11 I I 11 1111 I I11 11111111 III I III I III III I I I I I III 1111111 
Sbjct : 403 accatccaraactlatgcaa,cggggccgcaarcartgcaaracccatccccactttgt, 462 
Query: 410 attccctaccgctgctta,ttggtgagtttgtaagtgatgcccttctcgttcctgacaa, 469 
11111111 I 111111111111111111111111111111111111111111111111111 
Sbjct : 463 attccctaccgctgcttagttggtgagtttgtaagtgatgcccttctcgttcctgacaag 522 
Query: 470 tgcaaattcttacaccaggagaggatggatgtttgcgaaactcatcttcactggcacacc 529 
11111111 I I I I11 I 11 11111 I 11111111111111111111111 11111111111111 
Sbjct : 523 tgcaaattcttacaccaggagaggatggatgtttgcgaaactcatcttcactggcacacc 5B2 
Query: 530 gtcgccaaagagacatgcagt,a,aa,a,taccaacttgcatgactac"catgtt,ct, 5S9 
111111111 11111 1111111111111111111111111111111111111111111111 
Sbjct : 583 gtcgccaaararacatgcagtga,aagagtaccaacttgcatgactacggcatgttgct, 642 
Query: 590 ccct,cggaattga 603 
11111111111111 
Sbjct : 643 ccctgcggaattga 656 
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APP/pcDNA3 sequencing (T7 primer) (APPwt-T7.scf) 
>giI13325111IgbIBC004369.11 Homo sapiens amyloid beta (A4) precursor protein (protease 
nexin-II, Alzhei.er disease), mRNA (cDN! clone 
IYAGE:3639S99), complete cds 
Length = 1319 
Score = 952 bits (480), Expect = 0.0 
Identities - 480/480 (10~) 
Strand - Plus I Plus 
Query: ctggaggtaeeeactgatggtaatgetggcetgctggctgaaececagattgceatgtte 60 
I 11111111 111111 11111111111111111111111111111111111 1111111111 
Sbjct : 178 ctggaggtaeceactgatggtaatgctggcctgctggctgaaccccagattgccatgttc 237 
Query: 61 tgtggcagaetgaacatgcacatgaatgtceagaatgggaagtgggattcagateeatea 120 
I III 11111111111111111111111111111111111111111111111111111111 
Sbjct : 238 tgtggcagaetgaacatgcacatgaatgteeagaatgggaagtgggattcagatceatea 297 
Query: 121 gggaccaaaacctgcattgataccaaggaaggcatcctgcagtattgccaagaagtctac 180 
11 1111 111111111111111111111111111111111111111111111111111111 
Sbjct : 298 gggaeeaaaaeetgcattgataecaaggaaggcatcctgcagtattgceaagaagtctac 357 
Query: 1Bl cctgaactgcagatcaccaatgtggtagaagccaaccaaccagtgaceatecagaaetgg 240 
11 I 1111111111111111111111111111111111111111111111111 11111111 
Sbjct: 358 cctgaactgcagatcaccaatgtggtagaagccaaccaaccagtgaccatccagaactgg 417 
Query: 241 tgcaagcggggccgcaagcagtgcaagacccatceccactttgtgattccetaccgctge 300 
11 11 I 111111111111111111111 111111 1111 11111 1111111111111111111 
Sbj ct: 418 tgeaagcggggccgcaagcagtgcaagacccatccccactttgtgattccctaccgctge 477 
Query: 301 ttagttggtgagtttgtaagtgatgcccttctcgttcetgacaagtgcaaattcttaeae 360 
111111111111111111111111111111111111111111111111111111111111 
Sbj ct : 478 ttagttggtgagtttgtaagtgatgcccttctcgttcctgacaagtgcaaattcttacae 537 
Query: 361 caggagaggatggatgtttgcgaaaeteatcttcactggcaeaccgtegccaaagagaca 420 
I 11 I11 I11 1111 11 1111111 1111111 1111111111111111111111111111111 
Sbjct: 538 caggagaggatggatgtttgcgaaactcatcttcactggcacaecgtcgecaaagagaca 597 
Query: 421 tgcagtgagaagagtaccaacttgcatgactacggcatgttgctgccetgc"aattgae 480 
11 11111111 III 11 I III 111111 I 111111 111111111111 1111111111111111 
Sbjct : 598 tgcagtgagaagagtaccaacttgcatgactacggcatgttgctgccctgcggaattgae 657 
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APP/pEGFP-NI sequencing (AGI-pEGFPNlrev.sct) 
>giI133251111,bIBC004369,11 11 Hoao sapiens amyloid beta (AA) preCUrSor protein (protease 
nexin- II. Aliheimer disease). mRNA (cDNA clone 
lUAOE:3639599). complete cds 
Length = 1319 
Score = 1310 bits (661). Expect = 0,0 
Identities = 661/661 (100~) 
Strand - Plus I Plus 
Que ~ : 115 atgctgcccggtttggcactgctcctgctggccgcctggacggctcgggcgctggaggta 174 
111111111111111111111111111111111111111111111111111111111111 
Sbjct: 127 atgctgcccggtttggcactgctcctgctggccgcctggacggctcgggcgctggaggta 186 
Que~: 175 cccact,atggtaat,ctg,cctgct"ctgaaccccagattgccatgttctgtggcaga 234 
111111111111111111111111111111111111111111111111111111111111 
Sbjct : 187 cccactgatggtaatgctggCctgctggctgaaccccagattgccatgttctgtggcaga 246 
Que~: 235 ctgaacatgcacatgaatgtccagaatgggaagtgggattcagatccatcagggaccaaa 294 
111111111111111111111111111111111111111111111111111111111111 
Sbjct : 247 ctgaacatgcacatgaatgtccagaatgggaagtg"attcagatccatca"gaccaaa 306 
Que~: 295 acctgcattgataccaaggaaggcatcctgcagtattgccaagaagtctaccctgaactg 354 
111111111111111111111111111111111111111111111111111111111111 
Sbj ct : 307 acctgcattgataccaaggaaggcatcctgcagtattgccaagaagtctaccctgaactg 366 
Que~ : 355 cagatcaccaatgtggtagaa,ccaaccaacca,tgaccatccagaactggtgcaagCgg 414 
111111111111111111111111111111111111111111111111111111111111 
Sbjct : 367 cagatcaccaatgtggtagaagccaaccaaccagtgaccatccagaactggtgcaagCgg 426 
Que~: 415 ggccgcaagcaztgcaagacccatccccactttgtgattccctaccgctgcttagttggt 474 
111111111111111111111111111111111111111111111111111111111111 
Sbjct : 427 ggccgcaagcagtgcaa,acccatccccactttgtgattccctaccgctgcttagttggt 486 
Que~: 475 gagtttgtaagtgatgcccttctcgttcctgacaagtgcaaattcttacaccaggagagg 534 
111111111111111111111111111111111111111111111111111111111111 
Sbjct: 487 gagtttgtaagtgatgcccttctcgttcctgacaagtgcaaattcttacaccaggagagg 546 
Que~: 535 atggatgtttgcgaaactcatcttcact"cacaccgtcgccaaagagacatgcagtgag 594 
111111111111111111111111111111111111111111111111111111111111 
Sbjct : 547 atggatgtttgcgaaactcatcttcactggcacaccgtcgccaaagagacatgcagtgag 606 
Que~: 595 aagagtaccaacttgcatgactacggcatgttgctgccctgcggaattgacaagttccga 654 
111111111111111111111111111111111111111111111111111111111111 
Sbjct : 607 aagagtaccaacttgcatgactac"catgttgctgccctgc"aattgacaagttccga 666 
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Neurosin/pCR2.1 TOPO (M13 rev primer) (NES-M13rev( -29).scf) 
>giI34189311IgbIBC015525.21 11 Homo sapiens kallikrein 6 (neurosin, zyme) , mRNA (cDNA clone 
1GC:9355 IMAGE: 3852344) , coaplete cds 
Len&th • 1500 
SCore - 963 bits (486), Expect - 0.0 
Identities - 486/486 (10~) 
Strand - Plus 1 Minus 
Que ry: 65 t caggg t cac t tggcc tgaa tgg t t t t t tgga tccag t t Cg tg tat c tgcagacg t tggt 124 
I I I I I 11 11 I 11 11 1111111111111 1111 I11 11111 11 1111 1111111111111 I I 
Sbjct: 958 tca&ggtcacttggcctgaatggttttttggatccagttcgtgtatctgcagacgttggt 899 
Query: 125 gtaaactcctggcttctcctttgatccac~atgttaccccatgacacaaticctcg 184 
I I I I11 11 I I 11 I I 1111 1111111 11 11 I I I I I 11 I I11 I11 11 1111111111111 11 
Sbjct: 898 gtagactcct"cttctccttt,atccacaggggat,ttaccccat,acacaaggcctcg 839 
Query: 185 ,aggt"tctccacataccagcggacccccagaatcaccct"ca"aatccttccc,ta 244 
111111111111111111111111111111111111111111111111111111111111 
Sbjct: 838 gaggtggtctccacataccagcggacccccagaatcaccct"ca"aatccttccc,ta 779 
Query: 245 cttctcatccccagcacacaacatgttctgggtgatctggccagggtaggcatgctcaca 304 
11 I I I I I I I I 11 I I 1111111111111 I I I I I 11 I 11 I III III I 11111111 11111 I I 
Sbjct : 778 cttctcatccccagcacacaacatgttctgggtgatctggccagggtaggcatgctcaca 719 
Query: 305 ctcctcacgggacaccaggtggatgtatgcacactggatggtgtcagggaaatcaccatc 364 
I I I I I 11 I I I I I11 1111111111111 I I I I I I I 11 I 11 I I 11 I 11111 111111111 11 
Sbjct : 718 ctcctcacgggacacca,gt"atgtatgcacactggatggtgtcagggaaatcaccatc 659 
Query: 365 t,ct,tctt,cccca,ccca"atgtggcagctggt"t,tt"ctgagcagtccctctc 424 
1111 1111111 " I " " " " 1111111111 " I11 " 11 " 11 " " I " " " " 11 Sbjct: 658 t,ct,tcttgcccca,cccaggatgtggcagctggt"t,tt"ct,a,ca,tccctctc 599 
Query: 425 ca,,,,aa,,,,ctggatga,ttcagaga,tttggct,,,c,t,cca,gcgcaacagcat 484 
11111111111111 " " " " " I11 1111111 " 11111111111 " " 11 " I " 11 
Sbjct : 598 caggggaag"gctggatgagttcagagagtttggctgggcgtgccaggcgcaacagcat 539 
Query: 485 gatgtcctggtcatggctggcggcatcatagtcagggtggatcacagcccggacaacaga 544 
I I I 11 I11 I 1111 I 1111111111111 I11 I I I I 1111 I I 11 11 I 1111111111111 I I 
Sbjct: 538 gatgtcctggtcatggctggcggcatcatagtcagggtggatcacagcccggacaacaga 479 
140 
NeurosinlpRSET A (T7 primer) (KLK6C-l-T7 . set) 
>gi 1>4189>11 l,bIBC015525 .21 11 Hoao sapiens kallikrein 6 (neurosin, zyme), rnRNA (cDNA clone 
XGC:93sS lXAGE:38s2344), conplete cds 
Length = 1500 
Score· 815 bits (411), Expect - 0.0 
Identities = 411/411 (10~) 
Strand D Plus I Plus 
Que~: 40 ateet"tecteaetcteattectecagcet~eae~aecaeaataagttg,t,eat 99 
111111111111111111111111111111111111111111111111111111111111 
Sbjct : 230 atiit"tgctgagtctgattgcticagcct~eaga"a&ca&aataagtt"tgeat 289 
Query: 100 ggcggaccctgcgacaagacatctcacccctaccaagctgccctctacacctcgggccac 159 
111111111111111111111111111111111111111111111111111111111111 
Sbjct: 290 ggc"accctgcgacaacacatctcacccctaccaagctgccctctacacctc"gccac 349 
Que~: 160 ttgctct,t"tgg"tccttatccatccactgtgggtcetcacagctgcceactgcaaa 219 
111111111111111111111111111111111111111111111111111111111111 
Sbjct: 350 ttgctctgtggtggggtccttatccatccactgtgggtcctcacagetgcccactgeaaa 409 
Que~: 220 aaaccgaatcttca"tcttcctg",aa,cataaccttcg,caaagggacagttccca, 279 
111111111111111111111111111111111111111111111111111111111111 
Sbjct : 410 aaaccgaatcttcaggtcttcctggggaagcataaccttcggcaaagggagagttcccag 469 
Query: 2BO gagcagagttctgttgtccgggctgtgatccaccctgactatgatgccgccagccatgac 339 
111111111111111111111111111111111111111111111111111111111111 
Sbjct: 470 gagcagagttctgttgtccg"ctgtgatecaccctgactatgatgccgccagccatgac 529 
Que~: 340 cag,acatcatgctgttgcgcctggcacgcccagccaaactctctgaactcatccagCCC 399 
111111111111111111111111111111111111111111111111111111111111 
Sbjct : 530 caggaeatcatgetgttgegcctggcacgeccagecaaaetctctgaacteatccagecc 589 
Que~: 400 cttcccct"acag"actgctcagccaacaccaccacctgccacatcctg 450 
111111111111111111111111111111111111111111111111111 
Sbjct: 590 cttcccctggagagggactgctcagccaacaccaccagctgccacatcctg 640 
141 
^ a s 1.45 File: NM484-1A-M13rev(-29).scf Sequence Name: (none) Run ended: (unknown) Page 1 of 2 
•‘ 10 30 40 50 60 70 80 ^ 
个 GCA GC TC GM TTA CCC TCAC TA AGGG fCTVTC C T G C fiG G ATTAAAC G A ATTC GCT C CACAGGG TCGC G ATGC TGCCCGG TCTGGCACTGCTCCTGCTGGCCGC 
0 120 130 140 150 160 170 180 190 200 G^ACGGCTCGGGCGCTGGAGGTACCCACTGATGGTAATGCTGGCCTGCTGGCTGAACCCCAGATTGCCATGTTCTGTGGCAGACTGAACATGCACAC 
lMMSfMMMk4Udkkk 
7 。 220 230 240 250 260 270 280 290 300 T^GTCC AG A AT G G G A AG T G G G AT TC AG ATCC ATC AG G G ACCAAAACCTGCATTG AT AC C A AG G AAG GC ATC C T G C AG T AT T GC C AAG A AG TC T ^  • 
MkhkllMkSimMlhMk 
310 320 330 340 350 360 370 380 390 
tJTGAACTGCAGATCACCAATGTGGTAGAAGCCAACCAACCAGTGACCATCCAGAACTGGTGCAAGCGGGGCCGCAAGCAGTGCAAGACCCAT 
n 
,O0 410 420 430 440 450 460 470 480 490 
t;CACTTTGTGATTCCCTACCGCTGCTTAGTTGGTGAGTTTGTAAGTGATGCCCTTCTCGTTCCTGACAAGTGCAAATTCTTACACCAGGAG 
^ M m m i M m M M r n i 
500 510 520 530 540 550 560 570 580 .ATGGATGTTTGCGAAACTCATCTTCACTGGCACACCGTCGCCAAAGAGACATGCAGTGAGAAGAGTACCAACTTGCATGACTACGGCATGT1： 
A . I 
「 5 9 0 600 610 620 630 640 650 660 670 680 
/ f G C C C T G C G G A A T T G A C A A G T T C C G A G G G G T A G A G T T T G T G T G T T G C C C A C T G G C T G A A G A A A G T G A C A A T G T G G A T T C T G C T G A T G C G G ; ^ G 
fttMrnhlmMMmM 
;hromas 1.45 File: APPwt-T7.scf Sequence Name: (none) Run ended: (unknown) Page 1 of 2 
“ 10 20 ？5 40 50 60 70 80 90 I M 1 
{ AGCT GC AC A TGC TGCCCGG TTTGGC C TGC TCC TGC TGGCCGCC TGG ATGGC TCGG GCGC TG G AGG TACCCAC TG A T G G T A A T G C TG GCC TGC TG GC T G AACCC C A G A 
yMkMMkkMUiiMkkl 
0 120 130 140 150 160 170 180 190 200 210 
T G C C A T G T T C T G T G G C A G A C T G AAC AT G C A C A T G A A T G T C C A G A A T G G G A A G T G G G A T T C A G A T C C A T C A G G G A C C A A A A C C T G C A T T G A T A C C A A G G A A G ； 
I I I 
220 230 240 250 260 270 280 290 300 
； C A T C C T G C A G T A T T G C C A A G A A G T C T A C C C T G A A C T G C A G A T C A C C A A T G T G G T A G A A G C C A A C C A A C C A G T G A C C A T C C A G A A C T G G T G C A A G C 
Mlkk_iiJkMtmMMik 
310 320 330 340 350 360 370 380 390 400 
G G G C C G C A A G C A G T G C A A G A C C C A T C C C C A C T T T G T G A T T C C C T A C C G C T G C T T A G T T G G T G A G T T T G T A A G T G A T G C C C T T C T C G T T C C T G A ' 
410 420 430 440 450 460 470 480 490 
^ , A G T G C A A A T T C T T A C A C C A G G A G A G G A T G G A T G T T T G C G A A A C T C A T C T T C A C T G G C A C A C C G T C G C C A A A G A G A C A T G C A G T G A G A A G A G T ； ^ 
500 510 520 530 540 550 560 570 580 
^ A A C T T G C A T G A C T A C G G C A T G T T G C T G C CC T G C GG A A T T G AC A A G T T C C G A G G G G T A G A G T T T G T G T G T T G C C C AC T G G C T G M A A AG 1 ： 
5 90 600 610 620 630 640 650 660 670 680 
A C A A T G T G G A T T C T G C T G A T G C G G A A G A G G A T G A C T C G G A T G T C T G G T G G G G CGG AGC AG AC AC AG A C T AT GC A G A T G G G T G AA GAC A A A 
；hfomas 1.45 File: AGl -pEGFPNl rev.scf Sequence Name: (none) Run ended: (unknown) Page 1 of 2 
10 20 30 40 50 60 70 80 90 100 110 
广 CA TCGGCGG AG GCGTG TftCGG TGGG ；GGTCTC ATAAGCAG AGC TG G T T TAG TG AACCGTCAG ATCC GC T A G C G C TAC C G G AC T C A G ATC TC G AGC TC AA GC T T GC C A( 
120 130 140 150 160 170 180 190 200 210 
c a t g c t g c c c g g t t t g g c a c t g c t c c t g c t g g c c g c c t g g a c g g c t c g g g c g c t g g a g g t a c c c a c t g a t g g t a a t g c t g g c c t g c t g g c t g a a c c c c a g 
ikidMid/iiMimihkhk 
i 220 230 240 250 260 270 280 290 300 310 
i i T G C C A T G T T C T G T G G C A G A C T G A A C A T G C A C A T G A A T G T C C A G A A T G G G A A G T G G G A T T C A G A T C C A T C A G G G A C C A A A A C C T G C A T T G A T A C C A A C ： 
I I I L I I I I I I I I 
i i i y 
320 330 340 350 360 370 380 390 400 
t A A G G C A T C C T G C A G T A T T G C C A A G A A G T C T A C C C T G A A C T G C A G A T C A C C A A T G T G G T A G A A G C C A A C C A A C C A G T G A C C A T C C A G A A C T G G T G C 
l i f t In iMM^iMUUwMMM 
10 420 430 440 450 460 470 480 490 500 
a g c g g g g c c g c a a g c a g t g c a a g a c c c a t c c c c a c t t t g t g a t t c c c t a c c g c t g c t t a g t t g g t g a g t t t g t a a g t g a t g c c c t t c t c g t t c c t 
m^kMltlMmkkMM 
510 520 530 540 550 560 570 580 590 600 
A C A A G T G C A A A T T C T T A C A C C A G G A G A G G A T G G A T G T T T G C G A A A C T C A T C T T C A C T G G C A C A C C G T C G C C A A A G A G A C A T G C A G T G A G A A G A G T A C 
LMUMkUMfJMUmlMjdl 
6 1 0 6 2 0 6 3 0 6 4 0 6 5 0 6 6 0 6 7 0 6 8 0 6 9 0 7 ( ： 




h 鍾 asl.45 File:NES-M13rev(-29).scf Sequence Name: (none) Run ended: (unknown) • ？明。1 二 
AX CO. GC TIG G ACCGA'G C G ATCc'^ i TA T mC G AMG TG TGC TG G AM" 了^ !^  J^ T TC AG GG TC AC TTG G C C TG AATG G T T T T T T G G ATC CA G T TCG TG TA T 
T G C A G A C G T T G G T G T A G A ? T C C T G 3 C T T " T C C T T T G A T C C A C A G ^ 
,CCAGAAT2?。ACCCTGGcJ&AATCCTTc25GTACTTCT2》VrCCCCAGCACM:AM:ATGTTCTGGGTGATCTGGCCM;GGTAGGCATGCTCM:ACTC 
310 3 2 0 3 3 0 T T T C ^ L G G A A A T C A C C A T C T G C T G T C T T G C C C C AGCCC AGG A T G T G G C A G C T G G T G ( TCACGGG AC ACC AGG TGG ATGTATGC AC AC TGG ATGGTGTC Abl. 
M m m i M K ^ A k t l ！ 410 420 440 r^TTrAGAGAGTTTGGCTGGGCGTGCCAGGCGCAACAGCATGATGTCCTGGTC rGTTGGC TG AGC AGTCCCTCTCCAGGGG AAGGGGCTGG ATGAGTTCAGAG A 
I 以 5 0 0 ' s i r 5 2 0 . P T G A C A A ? AG A A C T C T G C T C C T G G G A A C T C T C C C T T T G C C G . ^ A G T T AT G C T T C CC C AG 
TGGCTGGCGGC ATCATAGTCAGGGTGG ATC AC AGCCCGG ACAAC AG A AC 1 
H M k M k A ^ 
^ ^ ' e o o 6，20 二 6 二 ；,TGGAT AAGG AOC CC ACCAC AG AGC AAGTGGCCCG AGGTGTAG ？： 
A A G A C C T G A A G A T T C G G T T T T T T GC A G T G G G C AG C T G T G AG G ； C C C A C A G T G l . 
I I 
g g g i d j File: KLK6C-1-T7.scf Sequence Name: (none) Run ended: (unknown) Page 1 of 2 
T T T C C r r 20 30 40 50 60 70 80 90 100 
^^  rc A GA AA TTTTGTTTAACTTTMGAAGGAG AT ATAC A T A T G C ATC AT C A TC A TC ATC T T TG G T GC AT G G C G G ACCC T G C G ACAA G AC AT C T C AC C C C TAC( 
d^whrnMrnmrnmaJkif^MM 
K A G C T r r ^ r , 130 140 150 160 170 180 190 200 
't.C,CCTCTACACCTCGGGCCACTTGCTCTGTGGTGGGGTCCTTATCCATCCAATGTGGGTCCTCACAGCTGCCCACTGCAAAAAACCGAATCTT 




G C C AC o n . 320 330 340 350 360 370 380 390 
'^-CATGACCAGGACATCATGCTGTTGCGCCTGGCACGCCCAGCCAAACTCTCTGAACTCATCCAGCCCCTTCCCCTGGAGAGGGACTGI 
AM^khkmkmhiMhrnAiMi 
r-c fiG rr ^ .r, 410 420 430 440 450 460 470 480 
^^ AACACCACCAGCTGCCACATCCTGGGCTGGGGCAAGACAGC AG ATGGTGATTTCCC TGACACC ATCC A3 TG TGC AT fC ？T C C ACC T C ： 
rnmittMiMimkMhAAMJkmd 
500 510 520 530 540 55O 560 570 580 
jTGTCCCGTGAGG/GTGTGAOa J^ G C TACCCT G A:CAQ\TCACC<A ACAAAATGTTGTGTGCTG JGG AT GN' A (AG ；C G GA TA T G ;T T CC A GA 

























. / 、 .
 . ：
 - . - • - 、 。 - 〉 ： ： . . ： -
- •
 >









. . . - ” • • •

















 . . .
 . r
 • . 
.厂.、，.二一
 广. , i .v i r















 . . 






. 1 . .













 . . 
- .









. . . ‘ 
C U H K L i b r a r i e s 
0 0 4 2 7 9 2 3 2 
